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Abstract
Human stem cell models (CD34+ hematopoietic progenitors, embryonic stem cells and induced pluripotent
stem cells (iPSCs)) are powerful tools for the study of megakaryopoiesis and thrombopoiesis, particularly in
situations where mouse models are unavailable or do not accurately recapitulate human physiology or
development. In the first part of this thesis, we identified and characterized novel megakaryocyte (MK)
maturation stages in MK cultures derived from human stem cells. An immature, low granular (LG) MK pool
(defined by side scatter on flow cytometry) gives rise to a mature high granular (HG) pool, which then
becomes damaged by apoptosis and GPIbα (CD42b) shedding. We define an undamaged HG/CD42b+ MK
subpopulation, which endocytoses fluorescently-labeled coagulation factor V (FV) from the medium into
alpha-granules and releases functional FV+CD42b+ platelet-like particles in vitro and when infused into
immunodeficient mice. Importantly, these FV+ platelets have the same size distribution as infused human
donor platelets and are preferentially incorporated into clots after laser injury. Using drugs to protect HG MKs
from apoptosis and CD42b shedding, we also demonstrate that apoptosis precedes CD42b shedding and that
apoptosis inhibition enriches the FV+ HG/CD42b+ MKs, leading to increased platelet yield in vivo, but not
in vitro. These studies identify a transition between distinct MK populations in vitro, including one that is
primed for platelet release. Technologies to optimize and select these platelet-ready MKs may be important to
efficiently generate functional platelets from in vitro-grown MKs. In the second part of this thesis, we used
patient-specific iPSCs to model Thrombocytopenia Absent Radius (TAR) syndrome, a rare congenital
disorder characterized by low platelet counts and bilateral absence of the radius. We generated several iPSC
lines from patients and controls and confirmed that the patient lines had decreased expression of RBM8A, the
candidate disease gene for TAR syndrome. We differentiated patient and control iPSCs to hematopoietic
progenitor cells (HPCs) and MKs and showed that HPCs derived from TAR iPSCs exhibited decreased MK
colony-forming potential but differentiated normally into MKs in liquid culture. When we restored RBM8A
expression in TAR iPSCs using a doxycycline inducible system, we saw no effect on megakaryopoiesis. We
then knocked out RBM8A in TAR iPSCs and found that a complete deficiency in RBM8A expression was
lethal for iPSCs, HPCs, MKs and erythrocytes. These studies suggest that we were unable to determine a
specific role for RBM8A in primitive (embryonic) megakaryopoiesis and perhaps future studies to direct
iPSCs towards the definitive (adult) MK lineage may better elucidate RBM8A’s role in TAR syndrome.
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ABSTRACT 
UNDERSTANDING MEGAKARYOPOIESIS AND THROMBOPOIESIS USING  
HUMAN STEM CELLS MODELS 
Xiu Li Sim 
Paul Gadue 
 
Human stem cell models (CD34+ hematopoietic progenitors, embryonic stem cells and 
induced pluripotent stem cells (iPSCs)) are powerful tools for the study of 
megakaryopoiesis and thrombopoiesis, particularly in situations where mouse models 
are unavailable or do not accurately recapitulate human physiology or development. In 
the first part of this thesis, we identified and characterized novel megakaryocyte (MK) 
maturation stages in MK cultures derived from human stem cells. An immature, low 
granular (LG) MK pool (defined by side scatter on flow cytometry) gives rise to a mature 
high granular (HG) pool, which then becomes damaged by apoptosis and GPIbα 
(CD42b) shedding. We define an undamaged HG/CD42b+ MK subpopulation, which 
endocytoses fluorescently-labeled coagulation factor V (FV) from the medium into alpha-
granules and releases functional FV+CD42b+ platelet-like particles in vitro and when 
infused into immunodeficient mice. Importantly, these FV+ platelets have the same size 
distribution as infused human donor platelets and are preferentially incorporated into 
clots after laser injury. Using drugs to protect HG MKs from apoptosis and CD42b 
shedding, we also demonstrate that apoptosis precedes CD42b shedding and that 
apoptosis inhibition enriches the FV+ HG/CD42b+ MKs, leading to increased platelet 
yield in vivo, but not in vitro. These studies identify a transition between distinct MK 
populations in vitro, including one that is primed for platelet release. Technologies to 
optimize and select these platelet-ready MKs may be important to efficiently generate 
functional platelets from in vitro-grown MKs. In the second part of this thesis, we used 
	  	   v 
patient-specific iPSCs to model Thrombocytopenia Absent Radius (TAR) syndrome, a 
rare congenital disorder characterized by low platelet counts and bilateral absence of the 
radius. We generated several iPSC lines from patients and controls and confirmed that 
the patient lines had decreased expression of RBM8A, the candidate disease gene for 
TAR syndrome. We differentiated patient and control iPSCs to hematopoietic progenitor 
cells (HPCs) and MKs and showed that HPCs derived from TAR iPSCs exhibited 
decreased MK colony-forming potential but differentiated normally into MKs in liquid 
culture. When we restored RBM8A expression in TAR iPSCs using a doxycycline 
inducible system, we saw no effect on megakaryopoiesis. We then knocked out RBM8A 
in TAR iPSCs and found that a complete deficiency in RBM8A expression was lethal for 
iPSCs, HPCs, MKs and erythrocytes. These studies suggest that we were unable to 
determine a specific role for RBM8A in primitive (embryonic) megakaryopoiesis and 
perhaps future studies to direct iPSCs towards the definitive (adult) MK lineage may 
better elucidate RBM8A’s role in TAR syndrome.  
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CHAPTER 1 
Introduction and Overview 
 
1.1 Characteristics and Functions of Megakaryocytes (MKs) and Platelets  
Megakaryocytes (MKs) are rare, large, polyploid blood cells present in the bone marrow1 
at a low frequency of 1 in 10,000 nucleated cells.2 The main function of a MK is to 
produce platelets, although secondary roles in regulating the hematopoietic stem cell 
(HSC) niche and function in the bone marrow have also been described.3,4 Platelets are 
anucleate cell fragments that are primarily important for hemostasis, but also have roles 
in modulating angiogenesis, inflammatory responses, lymphatic development, wound 
healing and repair.5–10  
 
1.2 Megakaryopoiesis and Thrombopoiesis  
HSCs give rise to MKs in a process termed megakaryopoiesis while MKs release 
platelets in a process termed thrombopoiesis.  
 
1.2.1 Hierarchical Model of Hematopoiesis  
In the classical model of hematopoiesis, self-renewing, multi-potent HSCs give rise to all 
the blood lineages, including the MK lineage, through a series of increasingly committed 
progenitors. In this model, the HSC goes through a multi-potent progenitor stage 
followed by a common myeloid progenitor (CMP) stage before differentiating into bi-
potent granulocyte-macrophage progenitors (GMPs) and megakaryocyte-erythrocyte 
progenitors (MEPs)11–14 (Figure 1.1). MEPs, as its name suggests, give rise to MKs and 
erythrocytes. However, recent studies suggested that there may be more straightforward 
pathways going from HSCs to MKs, with the identification of MK/platelet-biased HSCs, 
which directly give rise to MK progenitors (Figure 1.1).15–18 The evidence for these 
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differentiation pathways came from studies of the mouse hematopoietic system and 
whether the same hematopoietic hierarchy holds true for humans remains to be tested.  
 
1.2.2 Primitive and Definitive Megakaryopoiesis  
The understanding of megakaryopoiesis is further complicated by the separation of 
hematopoiesis into two distinct waves during development. The first wave of 
hematopoiesis, termed primitive hematopoiesis, occurs in the yolk sac of the developing 
embryo.19,20 Primitive hematopoiesis generates predominantly embryonic red blood cells, 
macrophages, MKs and platelets.21,22 The second wave of hematopoiesis, termed 
definitive hematopoiesis, starts in the yolk sac, but migrates to the aorta-gonad-
mesonephros (AGM) region and then the fetal liver, before finally settling in the bone 
marrow.19 HSCs arise during the definitive hematopoietic phase in the AGM and give 
rise to the full range of blood lineages.  
 
Studies have suggested that primitive and definitive megakaryopoiesis may be regulated 
differently,23,24 resulting in functional changes with ontogeny. Embryonic and fetal MKs 
are known to be more proliferative than adult MKs and produce platelets quickly without 
reaching high ploidy.22,25–27 In contrast, adult MKs have increased ploidy as compared to 
embryonic and fetal MKs and are more efficient in releasing platelets.25 Transcriptome 
profiling of primitive yolk sac MKs, definitive fetal liver MKs and adult MKs revealed that 
more than 1/3 of the genes that were continuously upregulated with MK ontogeny 
included cytoskeleton proteins and proteins involved in polyploidization, proplatelet 
formation and platelet functions, a probable explanation for why definitive adult MKs 
have higher ploidy and are likely more efficient platelet producers than primitive 
embryonic MKs.24 Further studies are necessary to better understand exactly how 
megakaryopoiesis changes with ontogeny and how different are the resulting MKs and 
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platelets in terms of function and characteristics. These differences are important 
especially since MKs derived from human embryonic stem cells (ESCs) and human 
induced pluripotent stem cell (iPSCs) are more similar to embryonic/fetal MKs than adult 
MKs,24,28,29 raising implications for the generation of stem cell-derived MKs and platelets 
for transfusions.  
 
1.2.3 Changes Accompanying MK Maturation  
Megakaryopoiesis is driven mainly by thrombopoietin (TPO)30–32 and is characterized by 
the upregulation of MK-specific cell surface markers (CD41, CD42a, CD42b, c-mpl)33 
and the expression of transcription factors associated with MK development (e.g. 
GATA1, FLI1, RUNX1, NFE2 etc).34 The resulting MKs undergo a complex maturation 
process, which involves 1) endomitosis to become a large polyploid cell,35 2) the 
formation of an invaginated membrane system (IMS),36 3) the formation of platelet-
specific granules37,38 (alpha granules, dense granules, lysosomes) and 4) the synthesis 
and endocytosis of granular content (RNA, platelet-specific proteins) to be distributed 
into platelets.39–44 (Figure 1.2). 
 
The role of high ploidy in MK function is not completely understood. Polyploidization is 
thought to help increase cell size and cytoplasmic volume to increase the number of 
platelets released from a single MK. Indeed, although MKs of lower ploidy (e.g. 
embryonic/fetal MKs, cord blood-derived MKs) are fully capable of releasing platelets, 
they are known to generate fewer platelets than MKs of high ploidy.22,25–27 Polyploidy 
may also influence terminal MK through functional gene amplification45 and coordinating 
expression of genes involved in DNA replication, platelet release and function.46 
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The IMS massively increases the membrane surface within the MK, serving as a 
membrane reservoir for platelet formation.36,47 The IMS also has a role in extending 
proplatelets through its interaction with actin filaments, which drive the proplatelet 
formation process.47,48  
 
Platelets derive most of their RNA and many proteins from the MKs.49,50 These proteins 
and RNA are pre-packaged in granules37,38 before being distributed into platelets. Most 
of these RNA and proteins are synthesized by the MKs,39,40 but some proteins, such as 
fibrinogen, immunoglobulins and coagulation factor V, are endocytosed by mature MKs 
from their environment and packaged for distribution into platelets.42,43,51 Platelets 
themselves, also endocytose certain proteins from their environment, such as fibrinogen 
and angiogenesis regulators like vascular endothelial growth factor (VEGF) and basic 
fibroblast growth factor (bFGF).43,52,53  
 
1.2.4 Sites and Process of Thrombopoiesis 
One model of thrombopoiesis involves mature MKs migrating from the osteoblastic 
niche, down a stromal cell-derived factor (SDF-1) gradient to the vascular niche,54,55 
where they extend proplatelets into the bone marrow sinusoids (Figure 1.2).56,57 These 
proplatelets then fragment to release platelets into the bloodstream. Evidence for the 
proplatelet model of thrombopoiesis comes from the observations of proplatelet 
structures in in vitro mouse and human MK cultures58,59 as well as live imaging and 
electron micrographs of MKs in the murine bone marrow, showing MKs extending 
proplatelet-like protrusions into microvessels.56,57,60,61 The directionality of proplatelet 
extension is guided by a transendothelial sphingosine 1-phosphate (S1P) gradient and 
the subsequent shedding of proplatelets into the circulation is prompted by high S1P 
concentrations in the blood.57 The observed proplatelet fragments that are shed are 
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considerably larger than platelets,56 but as they continue to mature and morph in the 
bloodstream with the help of vascular shear forces, they become smaller preplatelet 
intermediates and then finally, platelets.62 Recently, a new platelet release mechanism 
involving the rupturing of MKs through a interleukin-1a (IL-1a)-dependent pathway has 
been suggested (Figure 1.2).63 This mechanism results in the rapid release of large 
numbers of platelets, which may account for rapid thrombopoiesis in times of acute 
platelet needs.  
 
Apart from the bone marrow sinusoids, another primary site of platelet release is in the 
lung capillary bed, the first capillary bed encountered by any cell leaving the bone 
marrow. When MKs were isolated from blood entering and leaving the human lung by 
elutriation and manually counted on Wright-Giemsa-stained cytopsin slides, Levine et. 
al. detected 10 times more intact MKs in the vessels entering the lung capillary bed as 
compared to the vessels leaving the lung capillary bed.64 Moreover, 98% of the MKs 
leaving the lung had little or no cytoplasm remaining.64 These results, together with other 
independent observations of circulating MKs and platelets release in the lung, suggest 
that intact MKs leave the bone marrow, get trapped in the pulmonary capillaries and 
release platelets at this site.64–67 Evidence of higher platelet counts in the post-
pulmonary vessels compared to the pre-pulmonary vessels68 also support this theory. 
More recently, MKs were shown to release proplatelets and preplatelets in the lung by 
live imaging using intravital microscopy and it was estimated that the lung produces 
about half of the platelets in mice,69 suggesting that both the lung capillary bed and the 
bone marrow sinusoids are important sites of terminal platelet production.  
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1.2.5 Defects in megakaryopoiesis and thrombopoiesis 
Defects in megakaryopoiesis and/or thrombopoiesis can lead to thrombocytopenia or 
thrombocytosis, conditions where platelet counts are abnormally low or high, 
respectively. Understanding the underlying etiology of these abnormal conditions will 
often lead to the identification of proteins regulating important aspects of 
megakaryopoiesis and thrombopoiesis and a better understanding of the biology of 
these processes. Therefore, these studies have important clinical implications for the 
treatment of these conditions as well as the generation of in vitro platelets for 
transfusion.  
 
1.3 Thrombocytopenia Absent Radius (TAR) syndrome 
TAR syndrome is a rare congenital disorder characterized primarily by thrombocytopenia 
and bilateral absence of the radius.70 TAR patients may also present varying degrees of 
other clinical features, including skeletal malformations in the upper and lower limbs, 
cardiac abnormalities, cow’s milk allergy and several other unusual features.70 The 
etiology of TAR syndrome has not been elucidated but studies have shown that TAR 
patients have severely reduced number of mature MKs, suggesting that they may have 
defects in MK development and/or maturation.71–73 
 
Interestingly, platelet counts in TAR patients gradually improve with age and may 
approach near normal range in adulthood,70,74 suggesting that the defects in 
megakaryopoiesis or thrombopoiesis may be specific to infancy.   
 
1.3.1 The Genetic Basis of TAR Syndrome 
Most TAR patients have a deletion of one copy of the RBM8A gene and a single 
nucleotide polymorphism (SNP) in the 5’ untranslated region (UTR) or first intron of the 
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intact copy75 (Figure 1.3). The deletion of the RBM8A gene is most commonly due to a 
microdeletion on chromosome 1q21.1,75,76 but can also be a result of null mutations.75 
The microdeletion in TAR patients varies in size, but a minimum deletion of 200 
kilobases (kb) has been described to cause TAR syndrome. The minimal deleted region 
encompasses 11 genes, including RBM8A,76 all of which have no known roles in 
megakaryopoiesis or thrombopoiesis. The strongest evidence for the involvement of 
RBM8A in TAR syndrome is the identification of 2 TAR patients, who have one null 
RBM8A allele and the 5’ UTR SNP in the intact RBM8A allele.75 The 5’ UTR SNP (G/A) 
and the first intronic SNP (G/C) are present in the normal population with frequencies of 
3.05% and 0.42% respectively and do not result in any abnormal phenotype when 
present in isolation.75 Additionally, family members of TAR patients, who are carriers of 
the 1q21.1 microdeletion present a normal phenotype,75,76 suggesting that 
haploinsufficiency of the genes in the microdeletion is not sufficient to cause TAR 
syndrome or any obvious hematologic/bone phenotype.   
 
Therefore, compound inheritance of a null RBM8A allele together with one of two low-
frequency SNPs in the non-coding region (5’ UTR/first intron) of the RBM8A gene is 
necessary to result in TAR syndrome.75 Although the exact role of the SNP is unclear, it 
has been hypothesized that the deletion and the SNP together result in sub-optimal 
expression of RBM8A,75 which may negatively impact megakaryopoiesis and/or 
thrombopoiesis.  
 
1.3.2 Y14 and the Exon Junction Complex 
The RBM8A gene encodes the Y14 protein, which is one of the proteins that make up 
the exon junction complex (EJC).77–79 The EJCs mark and bind to the exon junctions of 
spliced mRNAs and accompany the export of spliced mRNAs from the nucleus to the 
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cytoplasm, where they are being translated.80 The presence of the EJC on spliced 
mRNAs enhances the translation of the mRNAs.81 In particular, the EJC has a central 
role in mRNA surveillance and nonsense-mediated decay of mRNAs with premature 
stop codons.82–84 Given that the EJC is involved in these important general cellular 
functions, it is unsurprising that it is ubiquitously expressed85 and is present in all 
hematopoietic cells,75 thus it is unclear how a deficiency in Y14 or EJC function can lead 
to specific defects in megakaryopoiesis or thrombopoiesis. Albers et. al.75 suggested 
several possible hypotheses for the disease mechanism of TAR syndrome. Either there 
is a MK-specific deficiency in RBM8A/Y14 due to a MK-specific regulation of 
RBM8A/Y14 expression that is dependent on the non-coding SNP or that global 
deficiency of RBM8A/Y14 specifically regulate physiological mRNA abundance in a 
tissue-specific manner. However, all these hypotheses are speculative at this point.  
 
1.3.3 Animal Models of Y14 Deficiency 
Y14 is highly conserved between species.75 In Drosophila, knockdown of Y14’s ortholog 
(tsu) caused major defects in abdomen formation.86 In the zebra fish, knockdown of Y14 
led to extreme malformations and death at 2 days post-fertilization.75 Together, these 
data suggest that RBM8A/Y14 plays an important role in embryogenesis, but does not 
give us any information on how it can specifically impact megakaryopoiesis or 
thrombopoiesis. As the genetic cause of TAR syndrome was only uncovered recently in 
2012,75 there have not been any published reports on a mouse model of TAR syndrome.  
 
1.4 The Use of Human Stem Cell Models to Understand the Biology of 
Megakaryopoiesis and Thrombopoiesis 
Since MKs represent 0.01% of all the nucleated cells in the bone marrow,2 it is a 
challenge to study megakaryopoiesis or thrombopoiesis using primary human bone 
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marrow MKs. An alternative system to study human-specific MK biology is to use MKs 
differentiated from human stem cells.  
 
Since the identification of TPO as the main cytokine driving megakaryopoiesis,30–32 many 
laboratories have been successful in differentiating a variety of human stem cells into 
MKs and platelets.59,87–94 These human stem cell sources include ESCs, iPSCs, cord 
blood and adult CD34+ hematopoietic progenitors.  
 
ESCs and iPSCs are particularly attractive stem cell sources as they are self-renewable, 
proliferative and amenable to genetic manipulation. With these stem cell models, we are 
able to obtain large numbers of MKs with high purity, which makes the study of MKs 
much easier than purifying these cells from the bone marrow. Gene functions in 
megakaryopoiesis and thrombopoiesis can be investigated through knocking out or 
overexpression of these genes in stem cell-derived MKs. Additionally, iPSCs derived 
from patients with MK/platelet disorders can also be used for disease modeling as these 
cells carry all the genetic characteristics of the patient and differentiating these cells to 
MKs/platelets can recapitulate the disease phenotype and reveal interesting 
mechanisms. 
 
However, ESCs/iPSCs are limited in that their differentiation into MKs recapitulates 
primitive (embryonic) megakaryopoiesis,28 so the findings from these models may not be 
applicable to definitive (adult) megakaryopoiesis. For that, we can utilize adult CD34+ 
hematopoietic progenitors, which have the limitation of being donor-dependent, but are 
able to recapitulate definitive megakaryopoiesis.  
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1.5 Stem Cell-derived Platelets for Transfusions 
Other than the study of human MK/platelet biology, another important potential 
application of stem cell-derived MKs and platelets is the use of these cells for 
transfusions.  
 
1.5.1 The Clinical Demand for Platelets 
Platelet transfusions are used to treat severe thrombocytopenia and bleeding associated 
with trauma and surgery.95,96 More than a million platelet transfusions are being 
performed yearly in the United States alone.97 Although the clinical demand for platelets 
has increased over the years, the number of donors has shown a slight decrease, 
leading to a perpetual shortage of donor platelets for transfusion.97 Additionally, the 
quality of human donor platelets is highly variable depending on the donor and there 
may be issues with immunogenicity, even with matched donors.98 Donor platelets have 
to be stored at room temperature,99 which increases the risk of bacterial contamination. 
Finally, donor platelets have a short shelf life of 5 days,99 which means that many 
platelet units are discarded before they can be used, leading to high wastage.97  
 
1.5.2 In Vitro-generated Platelets for Transfusions 
The idea of using stem cell-derived platelets to replace or supplement human donor 
platelets for transfusion is a very attractive one for the following reasons:  
1) Since stem cells are self-renewable, we can technically generate unlimited 
numbers of platelets for transfusion. 
2) Since platelets are anucleate, the stem cell-derived platelet product can be 
irradiated to kill off any contaminating cell types, especially undifferentiated stem 
cells, which have teratoma-forming potential. 
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3) Stem cells can be engineered to be human leukocyte antigen (HLA)-deficient to 
generate “universal” platelets,90 which can be transfused into any individual 
without immunogenicity issues. 
4) Platelets with enhanced qualities, such as a longer circulating half-life, can be 
generated through genetic engineering of the parent stem cell.  
 
The first in vitro-generated platelets were described more than 20 years ago.59 Despite 
improvements in the efficiency of platelet generation, the in vitro-generated stem cell-
derived platelets remain too expensive to be a feasible source for donor platelet 
replacement in transfusions. Not to mention, the functionality of these in vitro-generated 
platelets is highly questionable as they have not been rigorously assessed and 
compared to the gold standard, human donor platelets. 
 
1.5.3 Current Platelet Yields per MK 
Thrombopoiesis in vivo is a highly efficient process; each MK release thousands of 
platelets into the bloodstream.100 Traditionally, in vitro-generated platelets from static MK 
cultures are purified using centrifugation methods89,90,101 (Figure 1.4). Newer and better 
methods for generating platelets in vitro make use of platelet bioreactors,102–106 which 
more accurately mimic the in vivo environment with the incorporation of vascular shear 
stress, extracellular matrix components and endothelial cell contacts (Figure 1.4). Yet 
the best in vitro platelet yield per MK is 30,90 which pales in comparison to the in vivo 
yield of >1000.100  
 
To put things in perspective, a unit of platelets for transfusion contains 3 x 1011 platelets. 
To get one unit of platelets with the current yield, we need 1 x 1010 MKs. Since each 
iPSC can give rise to 16 MKs,90 we would need 625 million iPSCs or approximately 100 
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6-well plates of iPSCs as starting material to get a unit of platelets. At this efficiency, the 
process is prohibitively expensive.  
 
 
1.5.4 Are In Vitro-generated Platelets Functional?  
The gold standard assay for assessing platelet functionality is light transmission 
aggregometry (LTA), which evaluates the kinetics and extent of platelet aggregation in 
the presence of stimuli. LTA requires a large number of platelets, so low yields from in 
vitro platelet generation have made it impossible for this technique to be the standard for 
assessing functionality. Feng et. al.90 were the first group to achieve sufficient number of 
in vitro-generated platelets to be tested by LTA. The poor functionality of these platelets 
was obvious as they had an activation curve similar to cord blood platelets, which were 
known to be hyporesponsive to physiological agonists as compared to adult platelets.107–
109 Many groups assessed the functionality of in vitro-generated platelets by examining 
their ability to activate in response to platelet agonists (such as thrombin or adenosine 
diphosphate (ADP)). The activation response include: 1) changes in conformation of the 
surface αIIbβ3 receptor, which can be detected by PAC-1 antibody binding110,111 and 2) 
surface exposure of P-selectin resulting from alpha-granule release. While human donor 
platelets show a dramatic shift in PAC-1 binding and P-selectin exposure in these 
assays, the in vitro-generated platelets showed much weaker responses to the same 
stimulation,90–92,112 suggesting subpar functionality. 
 
Another assay to evaluate platelet functionality is to examine their incorporation into a 
growing thrombus in vivo using a laser injury model. In this assay, a laser injury induced 
in the arterioles of the mouse’s cremaster muscle leads to the formation of a thrombus. 
When human MKs or platelets are infused prior to the induction of laser injury, the 
functional human platelets incorporate into the clot through a αIIbβ3 receptor-specific 
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interaction.89,90,113 This assay is limited because even human donor platelets show very 
low incorporation rates into the mouse thrombus due to the overwhelming number of 
mouse platelets and the poor ability of human platelets to interact with mouse von 
willebrand factor (VWF),114 a key process in adhesion.115 The development of a mouse 
model expressing VWF with enhanced specificity for human platelets,114 will be very 
useful for assessing the functionality of in vitro-generated platelets. 
Electron microscopy has also been performed on in vitro-generated platelets to compare 
their morphology and ultrastructural features to those of human donor platelets.89,90,92,112 
But these studies showcase a few individual platelets, which may not be representative 
of the whole platelet product.  
 
Last but not least, a strong indication of the poor quality of in vitro-generated platelets is 
the rapid clearance rate of these platelets by macrophages when infused into 
immunodeficient mice,90 presumably because these platelets are pre-activated. In 
contrast, when human donor platelets are infused into immunodeficient mice, they have 
a circulating half-life of 12 hours.113  
 
The limitations on the yield and functionality of in-vitro generated platelets suggest that 
there is a lot more to be learned about the biology of megakaryopoiesis and 
thrombopoiesis so that we can further optimize the process of platelet generation from 
stem cell sources. While understanding how megakaryopoiesis and thrombopoiesis work 
in vivo using mouse models is very important, we also need a better understanding of 
these processes in vitro using human stem cell models.  
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1.5.5 Platelet Production In Vivo from Infused MKs 
An alternative approach to generate platelets is to infuse stem cell-derived MKs into 
mice or potentially humans and allow them to release platelets in vivo (Figure 1.4). 
When cultured human MKs are infused into immunodeficient mice, the platelets derived 
from these MKs circulate with a half-life of 12 hours, similar to infused human donor 
platelets, suggesting that the platelets produced in vivo following MK infusion are of 
higher quality than those generated in vitro.113 The infused MKs get trapped in the lung 
pulmonary bed and release platelets over a 2-4 hour period.113 The platelets derived 
from infused MKs are of similar size to human donor platelets and incorporate into clots 
following laser injury.113 These data suggest that MK transfusions may be a possible 
alternative to platelet transfusions.   
 
In fact, three clinical trials have been performed to assess the safety and feasibility of 
infusing ex vivo generated MK progenitors into cancer patients.116–118 These studies 
showed safety and tolerability of autologous transfusions of MK progenitors 
differentiated ex vivo from CD34+ hematopoietic progenitors. However, the efficacy of 
these treatments is unclear as most patients required additional platelet transfusion 
support and the lag time to platelet recovery was quite long for those that did not require 
additional platelet transfusions. Although the infusion of MKs or MK progenitors into 
patients may be possible, we will require more extensive studies for this method to 
become a clinical reality.  
 
1.6 Overview of Research Goals 
The overarching goal of my thesis work is to improve our understanding of the biology of 
megakaryopoiesis and thrombopoiesis using human stem cell models, as this 
knowledge is extremely important for the optimization of in vitro platelet generation for 
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transfusions. The two main approaches I have taken are to: 1) identify and enrich the 
mature platelet-producing MK population within the heterogeneous, asynchronous 
human MK culture and 2) elucidate the disease mechanism of TAR syndrome using 
patient-specific iPSCs as a disease model.  
 
1.6.1 Identification and Enrichment of the Mature Platelet-producing MK Population  
One of the difficulties with the manufacture of in vitro platelets is deciding the optimum 
time frame to harvest the platelets. This is complicated because the in vitro human MK 
culture is a heterogeneous and asynchronous mixture of MKs at different stages of 
maturation and platelet release occurs continuously over a certain time frame as the 
MKs mature. Although we have some idea of the changes that accompany the MK 
maturation process, we do not have a clear idea of what actually defines a final mature 
MK that is primed and ready to release platelets. We hypothesize that the mature MK at 
its prime may be a transient stage that needs to be captured to improve the quality and 
yield of in vitro platelets, thus my specific goal is to identify and enrich this specific stage 
of MKs to improve the process of in vitro platelet generation.  
 
1.6.2 Elucidation of the Disease Mechanism of TAR Syndrome Using Patient-Specific 
Induced Pluripotent Stem Cells (iPSCs) 
The growing ease of reprogramming patient samples to iPSCs and the improvements in 
MK/platelet differentiation protocols has made disease modeling using patient-specific 
iPSCs a feasible strategy for understanding disease mechanisms and identifying novel 
key proteins that regulate megakaryopoiesis and thrombopoiesis. As described 
previously, TAR syndrome has a complicated genetic basis and RBM8A/Y14 is the most 
probable candidate gene/protein responsible for the disease pathogenesis. However, it 
remains unclear exactly how RBM8A/Y14 deficiency results in thrombocytopenia in 
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these patients. Hence, my specific goal for this project is to use patient-specific iPSCs as 
a disease model to investigate the role of RBM8A/Y14 in the disease mechanism of TAR 
syndrome. As RBM8A/Y14 has no known roles in megakaryopoiesis or thrombopoiesis, 
elucidating the disease mechanism will provide insights into an unknown area of MK and 
platelet biology, which may have implications for the treatment of TAR syndrome as well 
as the in vitro generation of platelets for transfusions.  
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Figure 1.1 
 
 
 
Figure 1.1: Model of Hematopoiesis (A) The long term-hematopoietic stem cell (LT-
HSC) and the short term-hematopoietic stem cell (ST-HSC) in the bone marrow are at 
the top of the hematopoietic hierarchy and give rise to all the blood lineages. (B) The 
quiescent HSCs can either self-renew or differentiate into proliferative multi-potent 
progenitors (MPPs), which undergo further differentiation into common myeloid 
progenitors (CMPs) or common lymphoid progenitor (CLPs), with more restrictive 
hematopoietic potential. (C) The CLP gives rise to B cells, T cells and natural killer (NK) 
cells. (D) The CMP can develop into a megakaryocyte-erythroid progenitor (MEP) or a 
granulocyte-monocyte progenitor (GMP). (E) GMPs give rise to neutrophils, basophils, 
eosinophils, monocytes and macrophages. (F) MEPs give rise to megakaryocytes 
(MKs), which produce platelets, and erythrocytes. (G) Within the HSC population, there 
is a subpopulation is platelet/MK-biased, which can differentiate directly into MK 
progenitors (MkPs) that give rise to MKs and platelets only. 
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Figure 1.2 
 
Figure 1.2: Model of Megakaryopoiesis and Thrombopoiesis (A) HSCs give rise to 
MKs through pathways illustrated in Figure 1.1. As MKs mature, there is an increase in 
surface expression of MK-specific receptors (CD41, CD61, CD42a, CD42b), an increase 
in ploidy, granules (alpha granules, dense granules) and granular content, as well as the 
formation of a complex IMS. (B) The fully mature MK migrates down the stromal-derived 
factor 1 (SDF-1) gradient from the osteoblastic niche to the vascular niche, where it 
extends proplatelets (C), which fragment to release pre-platelets into the bone marrow 
sinusoids. (D) Pre-platelet fragments are further shaped by vascular shear forces to 
become platelets. Intact mature MKs also migrate out of the bone marrow and release 
platelets in the lung capillary bed through similar processes. (E) Mature MKs could also 
undergo IL-1alpha-dependent rupture mechanism to release large numbers of platelets 
rapidly, potentially when acute needs arise.  
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Figure 1.3 
 
 
 
Figure 1.3: The Genetic Basis of TAR Syndrome (A) Most TAR patients have a 
minimum deletion of 200 kb in the chromosome region of 1q21.1, which results in the 
loss of one copy of 12 genes, including the RBM8A gene. They also have a SNP in the 
5’ UTR (G/A) or first intron (G/C). Both the deletion and one of the SNPs must be 
present for TAR syndrome to occur. (B) 2 TAR patients have been identified to have a 
null mutation in RBM8A on one chromosome and a 5’ UTR (G/A) SNP on the intact 
RBM8A allele, a strong indication that RBM8A may be the candidate disease gene in 
TAR syndrome.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chromosome 1q21.1
200 kb 
deletion
H
FE
2
TX
N
IP
PO
LR
3G
L
AN
KR
D
34
LI
X1
L
RB
M
8A
G
N
RH
R2
PE
X1
1B
IT
G
A1
0
AN
KR
D
35
PI
AS
3
N
U
D
17
5’U
TR
 (G
/A
) o
r
Chromosome 1q21.1
 RBM8A
X
Null mutation
 in RBM8A
 1s
t i
nt
ro
n 
(G
/C
)
5’U
TR
 (G
/A
) 
 RBM8A
A B
	  	  	   20 
Figure 1.4 
 
 
 
Figure 1.4: Current Methodologies for Generating Stem Cell-derived Platelets (A) 
MKs differentiated from ESCs and iPSCs in static culture form proplatelets in culture. 
The platelets that are shed in culture can be purified from the culture medium by 
centrifugation methods. This method yields approximately 7 platelets per MK. (B) MKs 
can be infused into a platelet bioreactor, which enhances proplatelet formation with the 
incorporation of endothelial cell contacts, extracellular matrix components and shear 
stress, yielding about 30 platelets per MK. (C) MKs infused into immunodeficient mice 
travel to the lung capillary bed and release platelets into the circulation, yielding about 30 
platelets per MK.  
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CHAPTER 2 
Materials and Methods 
 
2.1 Culture and Maintenance of Human iPSCs 
TAR syndrome patient-specific iPSC lines (TAR1, TAR2, TAR128) and multiple control 
iPSC lines from related family members (CTL2, CTL129, CTL130) and unrelated wild-
type individuals (CTL3, CHOPWT4, CHOPWT6) were reprogrammed by the Stem Cell 
Core at the Children’s Hospital of Philadelphia (CHOP), using either a lentiviral (TAR1, 
CHOPWT6) or sendai viral (TAR2, CTL2, CTL3, TAR128, CTL129, CTL130, 
CHOPWT4) approach.  
 
iPSCs were maintained on irradiated mouse embryonic fibroblasts (MEFs) plated on 
gelatin-coated 6-well tissue culture plates. The human ES cell maintenance media 
consists of 85% DMEM/F12, 15% knockout serum replacement, 2 mM glutamine, 50 
U/ml penicillin, 50 µg/ml streptomycin, 100 µM non-essential amino acids, 0.075% 
sodium bicarbonate, 1 mM sodium pyruvate (all from Invitrogen), 10-4M β-
mercaptoethanol (Sigma) and 10 ng/ml human recombinant basic fibroblast growth 
factor (bFGF) (Stemgent). iPSCs were passaged every 4 to 6 days by dissociating with 
TrypLETM (Invitrogen) and replating with 10 µM Rho-associated protein kinase (ROCK) 
inhibitor (Y-27632) (TOCRIS). 
 
2.2 Differentiation of Primary Human CD34+ HPCs into MKs 
Human CD34+ HPCs, purchased from the Fred Hutchinson Cancer Research Center, 
Co-operative Center for Excellence in Hematology Hematopoietic Cell Processing and 
Repository Core, were differentiated into MKs for 16 days in a MK differentiation 
media.93  
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2.3 Differentiation of Human iPSCs to HPCs and MKs 
iPSCs were differentiated into HPCs as described previously.119 HPCs were 
differentiated into erythrocytes in a serum-free differentiation (SFD) medium (75% IMDM 
(Corning), 25% Hams-F12 (Corning), 50 U/ml penicillin, 50 µg/ml streptomycin, 0.05% 
BSA, 0.5X B-27 supplement (Gibco) and 0.5X N2 supplement (Gibco)) with recombinant 
human stem cell factor (SCF) (50 ng/ml) (R&D systems) and erythropoietin (EPO) (2 
U/ml) for 5 days before flow cytometric analysis. HPCs were differentiated into MKs in 
SFD medium with recombinant human SCF (50 ng/ml), interleukin-3 (IL-3) (10 ng/ml) 
(R&D systems) and thrombopoietin (TPO) (50 ng/ml) (R&D systems) for 5 days before 
flow cytometric analysis. HPCs can also be differentiated into MKs in the same MK 
differentiation medium93 as CD34+ HPCs.  
 
2.4 Fluorescence-activated Cell Sorting (FACS) 
Day 14 MKs were stained with CD42a-Phycoerythrin (PE) (BD Pharmingen) in pre-sort 
media (Iscove’s Modified Dulbecco’s Medium (IMDM) (Corning), 10% fetal bovine serum 
(FBS) (Tissue Culture Biologics), 1% DNase (Roche)) on ice for 30 minutes and washed 
twice prior to sorting. CD42a+ HG and LG MKs were sorted into post-sort media (IMDM, 
40% FBS, 1% DNase) and cultured separately for another 6 days.  
 
Day 11 or 14 MKs were pulse labeled with 200 nM of FV-Alexa-647 in MK differentiation 
media for 1 hour at 37°C. CD42b-PE (BD Pharmingen) antibody was added during the 
last 20 minutes of the labeling period. MKs were washed twice with pre-sort media prior 
to sorting. CD42blow/FV-, CD42bhigh/FV- and CD42bhigh/FV+ MKs were sorted into post-
sort media and lysed in lysis buffer provided in the RNAeasy micro kit (Invitrogen) before 
storing at -80°C. Cell sorting was performed using a FACS Aria II (Becton Dickinson).  
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2.5 Flow Cytometry  
Flow cytometry was performed using a FACSCanto II flow cytometer (Becton Dickinson). 
Flow cytometry data were analyzed using the FlowJo software program (Treestar). The 
full list of antibodies can be found in Tables 2.1 – 2.3. 
 
For staining of cell surface markers, cells were processed to obtain single cell 
suspensions. Single cells were stained with the appropriate antibodies in FACS buffer 
containing Dulbecco’s Phosphate Buffered Saline (PBS) (Corning) with 0.1% bovine 
serum albumin (BSA) (Sigma) and 0.1% sodium azide (Sigma), for 15 minutes at room 
temperature (RT), in the dark. Cells were washed twice in FACS buffer post-staining 
before flow cytometric analysis.   
 
For Annexin V staining, cells were stained in Annexin-binding buffer (10 mM HEPES, 
140 mM NaCl and 2.5 mM CaCl2, pH7.4) for 15 minutes at RT in the dark and diluted 
with Annexin-binding buffer before flow cytometric analysis. To detect DNA 
fragmentation, TUNEL staining was performed on MKs using the APO-DIRECT kit (BD 
Pharmingen) according to manufacturer’s instructions.  
 
For intracellular staining of alpha-granule proteins, cells were fixed in 1.6% 
paraformaldehyde (PFA) (Electron Microscopy Sciences) at 37°C for 30 minutes, then 
washed twice with FACS buffer to remove PFA. Fixed cells were stored in FACS buffer 
at 4 °C. Fixed cells were permeabilized and stained in saponin buffer (Biolegend) with 
the appropriate primary antibodies at RT for 30 minutes. Cells were washed twice in 
saponin buffer post-staining and incubated with the appropriate secondary antibodies at 
RT for 30 minutes. Finally, cells were washed twice in saponin buffer and resuspended 
in FACS buffer before flow cytometric analysis. 
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To determine RNA content, thiazole orange (TO) staining was performed on day 14 
MKs. A stock of TO (1 mg/ml) (Sigma) was prepared by dissolving powdered TO in 
100% methanol. MKs were stained with TO (100 ng/ml final concentration) for 15 
minutes at room temperature and washed twice before analyzing by flow cytometry.  
 
For ploidy analysis, MKs were stained with Vybrant DyeCycle Violet (Invitrogen) 
according to manufacturer’s instructions.  
 
2.6 Agonist Stimulation of MKs 
MKs were centrifuged at 200g for 5 minutes and resuspended in Tyrode’s salt solution 
(Sigma) with 0.1% BSA (Sigma) to a final concentration of 1-4 x 106 cells/ml. MKs were 
stained with anti-CD42a, anti-CD42b, PAC-1 (see Table 2.1) and stimulated with 500 
ng/ml of convulxin (Enzo) or 50 µM of protease-activated receptor 1 (PAR1) activating 
peptide in a final volume of 50 µl for 20 minutes at RT in the dark. 450 µl of ice cold 
Tyrode’s salt solution with 0.1% BSA was added to the MKs post-stimulation and kept on 
ice until flow cytometric analysis.  
 
2.7 Metalloproteinase Inhibitor and Apoptosis Inhibitor Treatment of MKs 
MKs were treated with metalloproteinase inhibitor GM6001 (Calbiochem) (100 µM) or 
pan-caspase inhibitor Q-VD-Oph (ApexBio) (25 µM) continuously from day 8 to 15 of MK 
differentiation. The effects of these treatments on apoptosis and CD42b shedding on 
MKs were analyzed using flow cytometry. The effects on platelet production were 
evaluated by infusing treated MKs into immunodeficient NSG mice (see section 2.10) 
and by analyzing platelet-like particles produced in vitro (see section 2.11).   
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2.8 Pulse Labeling of MKs with Coagulation Factor V (FV) 
MKs were pulse-labeled with FV by incubating with 200 nM of a previously described FV 
variant120 tagged with Alexa-488 or Alexa-647 for 1 hour at 37°C. MKs were washed with 
40 mls of IMDM to remove excess FV. MKs were analyzed at specified time points post-
incubation. The platelet-generating capability of FV-labeled MKs was evaluated by 
infusing MKs into NSG mice (see section 2.10) and by analyzing platelet-like particles 
produced in vitro (see section 2.11).   
 
2.9 Immunofluorescence Staining and Confocal Microscopy of MKs 
Day 11 or 14 MKs were adhered to fibronectin-coated glass coverslips. Adherent MKs 
were incubated with 200 nM of FV-Alexa-488 for 1 hour or 20 nM of FV-Alexa-488 
overnight at 37°C. Adherent MKs that were not incubated with FV-Alexa-488 were used 
as negative controls. Adherent MKs were fixed with 2% PFA in PBS for 20 minutes at 
RT and washed with sterile PBS prior to staining. MKs were costained with rabbit anti-
human von willebrand factor (VWF) (Dako) and goat anti-human CD42b (Santa Cruz) or 
mouse anti-human CD41 (Millipore) in PBS, 0.2% saponin, 0.1% BSA in the dark for 1 
hour at room temperature and washed 3 times with PBS. MKs were then incubated with 
secondary antibodies in PBS, 0.2% saponin, 0.1% BSA in the dark for 45 minutes at 
room temperature. Secondary antibodies included donkey anti-rabbit Alexa-647 
(Jackson) for VWF, donkey anti-goat Alexa-594 for CD42b (Thermo Fisher) and goat 
anti-mouse Alexa-594 for CD41 (Thermo Fisher). After secondary antibody incubation, 
MKs were washed with PBS before nuclear staining with DAPI in PBS, then washed 
again with PBS. A few drops of Vectashield was added to protect the fluorescence. 
Confocal imaging of MKs was performed using a DMi8 microscope (Leica Biosystems) 
equipped with a 63x Plan Apochromat objective (1.4NA) and a Hamamatsu Photonics 
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ORCA-Flash4.0 sCMOS digital camera. Images were acquired in z-stacks using a 0.2-
micron step size with VisiView (Visitron Systems) software.  
 
2.10 MK Infusion Studies in Immunodeficient Mice 
NSG mice were produced at the CHOP using breeders from Jackson Laboratory. 
Cultured human MKs (2-7 x 106) were infused through the tail vein into NSG male mice 
between 8-12 weeks of age. 10 µl of fresh whole blood was collected retro-orbitally from 
the same mouse at specified time points following the infusion of human MKs. To detect 
the presence of human platelets in the mouse circulation, whole blood was stained using 
mouse anti-human CD42a-PB and CD42b-APC antibodies (see Table 2.1). CHOP’s 
Institutional Animal Care and Use Committee approved all animal experiments. To 
determine the effect of Q-VD-Oph treatment on platelet production post-infusion, MKs 
were treated with Q-VD-Oph as described in section 2.7. To determine if FV-labeled 
MKs generated FV-labeled platelets when infused into NSG mice, day 11 MKs were 
labeled with FV as described in section 2.8. 
 
2.11 Analysis of In Vitro Platelet-like Particles  
To analyze in vitro platelet production from FV-labeled MKs, day 11 or 14 MKs were 
labeled with 200 nM of FV-Alexa-647 for 1 hour at 37 °C, washed twice and 
resuspended in fresh MK differentiation media. In vitro platelet-like particles were 
collected 24 hours post-labeling for analyses. To collect in vitro platelet-like particles, 
MKs were centrifuged at 335g for 3 minutes. The supernatant containing platelet-like 
particles was collected and 1 µM of prostaglandin E1 (PGE1, Sigma) was added to 
inhibit the activation of platelet-like particles during centrifugation. The supernatant was 
then centrifuged at 1455g for 8 minutes. The pellet of platelet-like particles was 
resuspended in final resuspension buffer made up of Tyrode’s buffer with 0.2% bovine 
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serum albumin (BSA, Sigma). CD42a, CD42b expression and Annexin V binding of 
platelet-like particles were analyzed by flow cytometry. Activation of platelet-like particles 
was performed with 50 µM of PAR1-activating peptide in final resuspension buffer and 
analyzed by flow cytometry. Human donor platelets were prepared as control.  
  
2.12 Cremaster Laser Injury Model for Thrombus Formation In Vivo 
To examine released human platelet incorporation into thrombi, laser injuries were 
induced in the creamster arterioles of NSG mice 30 minutes after the infusion of MKs 
labeled with FV and calcein and thrombus formation was recorded. Day 11 MKs (2 to 7 x 
106) MKs were labeled with FV-Alexa-488 as in section 2.8 and 2 µM calcein red-orange 
(ThermoFisher) for 20 minutes at 37°C before infusing into the jugular vein of NSG mice. 
To visualize the clot, anti-mouse CD41-Alexa647 Fab fragments (BD Pharmingen) were 
injected intravenously prior to the induction of laser injuries. All animal studies were 
approved by CHOP’s institutional committee for animal welfare. 
 
2.13 Preparation of Primary Human Bone Marrow Aspirates for Flow Cytometry  
20 mls of human bone marrow aspirates were drawn from the hip into syringes 
containing 5 mls of heparin. Aspirates were filtered through a 70 µm nylon mesh and 
diluted with Hanks Balanced Salt Solution (HBSS) (ThermoFisher). Diluted aspirates 
were layered over Percoll (GE healthcare) and spun at 400g for 30 minutes with no 
brake. The second layer from the top, including the red blood cells, was collected. Red 
blood cell lysis was performed with ammonium chloride (STEMCELL technologies) at a 
volume:volume ratio of 1:1 and incubated at room temperature for 10 minutes. Aspirates 
were then washed with HBSS twice and spun down at 400g for 5 minutes. Washed 
aspirates are diluted to 20 x 106 cells/ml and stained with anti-CD42a-PB and anti-
CD42b-PE antibodies (see Table 2.1) before flow cytometric analysis was performed.  
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2.14 Genotyping of Human iPSCs 
To check for the presence of disease-associated single nucleotide polymorphisms 
(SNPs) in the 5’ untranslated region (UTR) and the 3’ UTR, the appropriate regions were 
amplified by PCR using Platinum® Blue PCR SuperMix (Invitrogen) and then purified 
using NucleoSpin® Gel and PCR Clean-up (Macherey-Nagel) prior to sequencing. Table 
2.4 shows the sequences of primers used to amplify and sequence the specified 
regions.  
 
2.15 Vector Cloning for Targeting a Doxycycline-inducible System for Transgene 
Expression into the AAVS1 Locus 
Zinc finger nucleases (ZFNs) targeting the intron 1 of the AAVS1 gene121 were 
synthesized and subcloned into a Phosphoglycerate kinase (PGK) promoter-driven 
expression vector: PGK-AAVS1-ZFN-Left (addgene #60915) and PGK-AAVS1-ZFN-
Right (addgene #60916). Two targeting vectors with arms of homology to the AAVS1 
locus were constructed: 1) AAVS1-SA-2A-NEO-CAG-RTTA3 (addgene #60431) express 
a reverse tet activator (rtTA) driven by a constitutive chicken-actin (CAG) promoter and 
confers neomycin resistance and 2) AAVS1-SA-2A-PURO-TRE-RBM8A express 
RBM8A driven by a tet-response element (TRE) and confers puromycin resistance 
(Figure 2.1). The two targeting vectors are designed to confer dual drug resistance to 
double-targeted clones. To create the AAVS1-SA-2A-PURO-TRE-RBM8A, the coding 
cDNA sequence with a 106 base pair (bp) partial 3’ UTR of the human RBM8A gene 
(ENST00000583313.6) was cloned into the AAVS1-SA-2A-PURO-TRE-eGFP vector 
(addgene #22074), replacing the eGFP portion of the vector. 
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2.16 Targeting a Doxycycline-inducible System for Expressing RBM8A/Y14 into 
the AAVS1 Locus  
Matrigel (Corning) diluted 1:3 with Iscove’s Modification of DMEM (IMDM) (Corning)  (1:3 
diluted matrigel) was used to coat 6-well tissue culture dishes prior to the plating of 
irradiated drug resistant DR4 MEFs (ATCC SCRC-1045.1). TAR1 and TAR2 iPSC lines 
were plated on 1:3 diluted matrigel-coated plates with DR4 MEFs the day before 
transfection. 1.5 µg of each targeting vector and 0.2 µg of each expression vector were 
diluted in IMDM and mixed with 10.2 µl of XtremeGENE9 transfection reagent (Roche) to 
a final volume of 100 µl. The transfection mixture was left to incubate at room 
temperature for 20 minutes before it was added drop wise into a single well of iPSCs. 
Medium was changed the next day to remove the transfection reagent. Double-targeted 
clones were selected by a two-step drug selection procedure commencing 48 hours after 
transfection, with 0.5 µg/ml of puromycin (Sigma) for 2 days followed by 40 µg/ml of 
neomycin (G418) (Life Technologies) for 10 days. Surviving clones were manually 
picked and screened for integration of both targeting vectors by PCR and Southern blot 
analysis. A more detailed description of the protocol can be found in Sim X et al.122 
 
2.17 PCR Screen for Successful Targeting of the Doxycycline-inducible System 
into the AAVS1 Locus 
Genomic DNA from surviving clones post-drug selection was isolated using the DNeasy 
Blood and Tissue kit (Qiagen).  PCR was performed on genomic DNA using Platinum® 
Blue PCR SuperMix (Invitrogen). 3 sets of screening primers were used to check for the 
successful integration of both targeting vectors into the AAVS1 locus. The locations of 
the 3 screening primer sets are shown in Figure 2.1. The sequences of the primer sets, 
expected band sizes and the purposes of each primer sets are described in Table 2.5.  
 
	  	  	   30 
2.18 Southern Blot  
Southern blot analysis was performed to detect any off-target integration of targeting 
vectors into random regions of the genome. Genomic DNA from surviving clones post-
drug selection was isolated using the DNeasy Blood and Tissue kit (Qiagen). 5-10 µg of 
genomic DNA was digested overnight at 37°C using restriction enzyme SPH1-HF (New 
England Biolabs). Separation of digested genomic DNA was performed on a 0.7% 
agarose gel by electrophoresis. The separated genomic DNA was then transferred onto 
an Amersham Hybond-N+ membrane (GE Healthcare) using an upward capillary transfer 
method under alkaline conditions and cross-linked to the membrane by ultraviolet 
radiation. The membrane was blocked by incubating with for an hour with PerfectHybTM 
Plus hybridization buffer (Sigma) in a rotating tube in a hybridization oven set at 62 °C. A 
480 bp fragment digested from the targeting vector AAVS1-SA-2A-PURO-RBM8A using 
restriction enzyme BamHI (New England Biolabs) was used as the probe. The probe 
was radioactively labeled with 32P-α-dCTP using Prime-It II Random Primer Labeling kit 
(Agilent) prior to overnight hybridization with the membrane at 62 °C. The membrane 
was processed through a series of low stringency wash steps using 2X saline sodium 
citrate (SSC) buffer with 0.2% sodium dodecyl sulfate (SDS) at 25 °C, followed by high 
stringency wash steps using 0.2X SSC buffer with 0.2% SDS at 62 °C. The resulting 
membrane was exposed to BioMax MS film (Sigma) for 24 hours before developing. If 
the AAVS1 locus is correctly targeted with both constructs for the doxycycline inducible 
transgene expression system, the resulting film should show two bands that are 3.4 kb 
and 3.7 kb (Figure 2.1).  
 
2.19 Genome Editing Using CRISPR/Cas9 System 
Given RBM8A’s role in critical cellular functions, knocking out RBM8A is likely to be 
lethal, thus gene editing was carried out in the TAR2 iPSC line, which has doxycycline-
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inducible expression of RBM8A from the AAVS1 locus (referred to as TAR2 TRE-
RBM8A). Doxycycline (1 µg/ml) was added throughout the course of gene editing to 
maintain a basal level of RBM8A expression, in case knocking out RBM8A is lethal.  
 
To knock out RBM8A using CRISPR/Cas9 technology, guide RNAs (gRNAs) were 
designed to cut around the 5’ UTR/ ATG start site border of RBM8A such that it will not 
cut the RBM8A cDNA sequence that was previously targeted into the AAVS1 locus. A 
200 bp oligo repair template carrying arms of homology to the region around the cut site 
and also encoding a frameshift mutation that creates a stop codon 5 amino acids 
downstream from the starting methionine residue was designed. Homology-directed 
repair using the oligo repair template will result in a null RBM8A allele and the 
introduction of a XhoI restriction enzyme site, which can be used for screening 
successfully edited clones (Figure 2.2).  
 
The gRNA sequence: 5’-ATCTCGATCGAAGGCGAGATGG-3’ was cloned into an 
expression vector (addgene #41824) using the Gibson Assembly® cloning kit (New 
England Biolabs) as described in Mali et. al..123 TAR2.1 DT67 iPSCs were plated on 1:3 
diluted matrigel-coated 6-well plates with MEFs a day prior to transfection. 0.5 µg CAS9-
GFP plasmid (Addgene #44719), 0.5 µg gRNA expression plasmid and 1 µg oligo repair 
template were diluted with IMDM and mixed with 3 µl of XtremeGENE9 transfection 
reagent (Roche) to a final volume of 100 µl. The transfection mixture was incubated at 
room temperature for 20 minutes before it was added dropwise to 1 well of iPSCs. 18-24 
hours post-transfection, iPSCs were trypsinized and GFP+ cells were sorted and plated 
at low density (<10,000 cells per 10 cm dish) in human ES cell maintenance media with 
ROCK inhibitor (Y-27632) (TOCRIS) on 1:3 diluted matrigel-coated 10 cm dishes with 
MEFs. Single colonies that emerge after 10-12 days of culture were manually picked and 
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screened for mutations in RBM8A. Genomic DNA for mutation screening was isolated 
using the DNeasy Blood and Tissue kit (Qiagen). PCR primers were used to amplify a 
733 bp fragment, which will be cut by XhoI restriction enzyme into 579 bp and 154 bp 
fragments if the oligo repair template was integrated into the RBM8A locus. Table 2.6 
contains the list of primers used for screening and sequencing.  
 
2.20 Western Blot 
To determine Y14 protein expression, western blotting was performed on protein 
harvested from iPSCs. Confluent wells of iPSCs were treated with Accutase (Life 
Technologies) and passaged 1:1 into 6-well low cluster plate to deplete MEFs and to 
form embryoid bodies. iPSCs were cultured as embryoid bodies for 2 days before they 
were trypsinized into single cells and frozen as cell pellets in -80 °C. A 2X Sodium 
dodecyl sulfate (SDS) sample buffer stock, composed of 187.5 mM Tris-HCl (pH 6.8), 
6% SDS, 30% glycerol and 0.03% bromophenol blue, was prepared for protein 
extraction. Frozen cell pellets were lysed in 1X SDS sample buffer for protein extraction 
at a concentration of 2.5 x 106 cells per ml. Protein lysates were sonicated in pulsed 
mode for 10 seconds then boiled at 95 °C for 5 minutes and kept on ice until they were 
ready to be loaded onto the gel. 20 µl of protein lysate was loaded into each well of a 
NuPAGE® Novex 12% Bis-Tris gel (Invitrogen) and separated by electrophoresis in 1X 
NuPAGE® MOPS buffer (Invitrogen) and then transferred onto a polyvinylidene fluoride 
(PVDF) membrane  (Thermo Fisher). The membrane was blocked in 5% nonfat dry milk 
in PBS for at least 3 hours at 4 °C before incubating with primary antibodies against Y14 
(4C4) (Santa Cruz) and beta actin (Santa Cruz) diluted in 1% nonfat dry milk in PBS with 
0.1% Tween-20 (Sigma) (PBS-T) overnight at 4 °C. Anti-Y14 primary antibody was used 
at 1:200 dilution while anti-beta actin antibody was used at 1:500 dilution. Following 
primary antibody incubation, the membrane was washed twice for 10 minutes with PBS-
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T before it was incubated with goat-anti-mouse-horse radish peroxidase (HRP) 
secondary antibody (Biorad) (1:5000 dilution) in 1% milk/PBS-T at RT on a rocker for 2 
hours. The membrane was washed thrice for 5 minutes with PBS-T and then incubated 
with PierceTM enhanced chemilumescent (ECL) substrates (Thermo Fisher) before 
exposure to Hyblot CL autoradiography film (Denville Scientific) for developing. 
 
2.21 Reverse Transcription and Quantitative Real Time Polymerase Chain 
Reaction (qRT-PCR)   
Cells were lysed in lysis buffer provided in the RNAeasy micro kit (Invitrogen) and stored 
at -80 °C. Total RNA was extracted using the RNAeasy micro kit according to 
manufacturer’s instructions. Reverse transcription of total RNA to cDNA was performed 
using the SuperScriptTM III Reverse Transcriptase kit (Invitrogen). qRT-PCR reactions 
were performed using SYBR-GreenER qPCR Master Mix (Roche) on a LightCycler 480 
II (Roche). TATA box binding protein (TBP) was used as the housekeeping gene to 
determine relative gene expression.124 The primers used for qRT-PCR are listed in Table 
2.7.  
 
2.22 Colony Assays to Determine the Hematopoietic Potential of HPCs 
HPCs were plated in a methylcellulose-based medium, MethocultTM H4435 Enriched 
(STEMCELL technologies) in 35 mm dishes according to manufacturer’s instructions. 5 
– 10 x 103 HPCs were plated per 35 mm dish.  Colonies are counted 12-14 days after 
plating.  
 
2.23 MK Colony Assays to Determine the Megakaryocytic Potential of HPCs 
HPCs were plated in a collagen-based medium, MegaCultTM-C (Invitrogen) in double 
chamber slides according to manufacturer’s instructions. 5 – 10 x 103 HPCs were plated 
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per slide. Slides were fixed and stained to identify MK colonies after 12 days of culture. 
MK colonies are enumerated.  
 
2.24 Statistical Analysis  
All data are represented as mean ± standard error of the mean (SEM). Differences are 
analyzed using the Student’s t test in GraphPad Prism 5 and are considered significant if 
the p value is smaller than 0.05.  
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Table 2.1: Conjugated Antibodies for Flow Cytometry  
 
Fluorophore Antibody Dilution Company 
Phycoerythrin (PE) 
CD41a 1:50 BD Pharmingen 
CD42a 1:20 BD Pharmingen 
CD42b 1:20 BD Pharmingen 
PF4 1:100 LSBio 
SSEA4 1:2000 Biolegend 
Fluorescein Isothiocyanate (FITC) 
CD43 1:50 Biolegend 
CD91 (LRP1) 1:20 BD Pharmingen 
AnnexinV 1:20 Biolegend 
PAC-1 1:10 BD Pharmingen 
Pacific Blue(PB) 
CD42a 1:20 eBioscience 
CD45 1:100 Biolegend 
Allophycocyanin (APC) 
CD18 1:20 BD Pharmingen 
CD42b 1:20 Biolegend 
CD235a 1:10000 BD Pharmingen 
Alexa647 
CD309 (KDR) 1:100 Biolegend 
SSEA3 1:50 Biolegend 
AnnexinV 1:20 LifeTechnologies 
PECy7 CD31 1:100 Biolegend 
 
 
Table 2.2: Unconjugated Primary Antibodies for Flow Cytometry 
 
Antibody Species Dilution Company 
Basic Fibroblast Growth Factor (bFGF) Rabbit IgG 1:20 Abcam 
Vascular Endothelial Growth Factor (VEGF) Rabbit IgG 1:20 Abcam 
Endostatin (Col18A) Mouse IgG2b 1:100 Santa Cruz 
 
 
 
Table 2.3: Secondary Antibodies for Flow Cytometry 
 
Antibody Dilution Company 
Goat anti-rabbit-Alexa647 1:400 Jackson Immunoresearch 
Goat anti-mouse IgG2b-Alexa488 1:400 Jackson Immunoresearch 
Goat anti-mouse IgG1-Alexa488 1:400 Jackson Immunoresearch 
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Table 2.4: Primers for amplifying and sequencing SNPs in the 5’ and 3’ UTR 
 
Purpose Sequence 
Amplify 280 bp fragment in 
the 5’ UTR  
Forward: 5’-CAATTTGCGTGTTTTTACCGTGCAG-3’ 
Reverse: 5’-ATTTTCCTATTATAGCCTTCTCTCG-3’ 
Sequence 5’ UTR SNP Forward: 5’-CTTGACTGGCGACCTTTCCC-3’ 
Reverse: 5’-	  CCCAGCCTCGTGAAGATCTA-3’ 
Amplify 402 bp fragment in 
the 3’ UTR 
Forward: 5’-GGTCCACCAAAAGGCAAGAG-3’ 
Reverse: 5’-CCATACAGCCTTGCTATGCTTT-3’ 
Sequence 3’ UTR SNP Forward: 5’-AGGGCAAATACTGTCTGGGTG-3’ 
Reverse: 5’-CGCAACTCAAATACTACGCAT-3’ 
 
 
Table 2.5: Screening Primers for Generating a Doxycycline-Inducible RBM8A 
Expression System  
 
 
 
Table 2.6: Screening and Sequencing Primers for Generating RBM8A Knockout 
iPSCs 
 
Primer set Sequence 
RBM8A knock out screening 
primers 
Forward: 5’-CCAACCGTATTGCAACCAAG-3’ 
Reverse: 5’-GTTCCTCGATTCCCATCCTT-3’ 
RBM8A knockout sequencing 
primers 
Forward: 5’-ATTGGTCAGCTTGACTGGC-3’ 
Reverse: 5’-AGCCTTCTCTCGCACCTTC-3’ 
 
 
 
 
 
 
 
 
 
 
Primer Set and 
Purpose Sequence 
Expected 
Band 
Size 
WT-- Screen for the 
absence of WT band 
Forward: 5’-CCCCTATGTCCACTTCAGGA-3’ 
Reverse: 5’-CAGCTCAGGTTCTGGGAGAG-3’ 500 bp 
AAVS1-CAG --
Screen for the 
integration of the 
CAG-RTTA3 
plasmid 
Forward: 5’-GAGCATCTGACTTTGGCTAATA- 3’ 
Reverse: 5’-GAAGGATGCAGGACGAGAAA-3’ 1,920 bp 
AAVS1-TRE -- 
Screen for the 
integration of TRE-
RBM8A plasmid 
Forward: 5’-GCAATAGCATCACAAATTTCAC-3’ 
Reverse: Same as AAVS1-CAG-Reverse 1,380 bp 
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Table 2.7:  qRT-PCR primers 
 
 
Gene Primer sequence 
C-MYC Forward: 5’ –CAAATGCAACCTCACAACCTTGGC-3’ 
Reverse: 5’- GCCCAAAGTCCAATTTGAGGCAGT-3’ 
GATA1 Forward: 5’-CGAAACCGCAAGGCATCTGGAAA-3’ 
Reverse: 5’-GCCACCACCATAAAGCCACCA-3’ 
NFE2 Forward: 5’- GGGTGGAACTGCTGATGGGATTT-3’ 
Reverse: 5’- GTTGCCATTGTCATCCTCTTCTGG-3’ 
PF4 Forward: 5’- ACTGGAAGGACAGCCGGGAATAAA-3’ 
Reverse: 5’- TCAGTGCTCAGTGCGATGGGAAA-3’ 
RBM8A Forward: 5’- TTCATCTCAACCTCGACAGGCGAA-3’ 
Reverse: 5’-ATAGCAGCCTGGGCTTCCTTGTAT-3’ 
TBP Forward: 5’-TTGCTGAGAAGAGTGTGCTGGAGATG-3’ 
Reverse: 5’-CGTAAGGTGGCAGGCTGTTGTT-3’ 
TUBB1 Forward: 5’- GGATGGGCACTCTGCTCATGAAC-3’ 
Reverse: 5’- GTTGTAGGGCTCCACCACAGTG-3’ 
VWF Forward: 5’-CTGTGATGAGAACGGAGCCAATG-3’ 
Reverse: 5’-GCTGCACAGTCCATTCCTGAAC-3’ 
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Figure 2.1 
 
Figure 2.1 Design of Targeting Vectors and Screening Strategy for Generating a 
Doxycycline-Inducible Transgene Expression System Two targeting constructs 
AAVS1-SA-2A-NEO-CAG-RTTA3 (A) and AAVS1-SA-2A-PURO-TRE-RBM8A (B) are 
targeted into the AAVS1 locus (C). The two constructs carry arms of homology to the 
AAVS1 locus. The left and right arms of homology (LAOH and RAOH) are shown. The 
approximate locations of the 3 screening primer sets and the expected sizes of the PCR 
products are indicated. For Southern blotting, SphI restriction enzyme is used to digest 
the DNA. SphI restriction sites in the constructs and the endogenous locus and the 
expected sizes of the fragments detected by the probe are shown.  
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Figure 2.2 
 
Figure 2.2: Strategy for Generating RBM8A Knock-out iPSCs (A) The RBM8A gene 
consists of 6 exons as labeled. (B) (Top) Partial genomic sequence of the RBM8A gene 
between the 5’ UTR and exon 1. The guide RNA (gRNA) sequence used to target Cas9 
to the RBM8A gene is labeled in red. The PAM sequence (TGG) is shown in bold. The 
Cas9 cut site is indicated as shown. The ATG start site is highlighted with the green box. 
(Bottom) The partial sequence of the 200 bp oligo repair template is shown. Mutations to 
the original genomic sequence are shown in pink. The G/C mutation at the PAM 
sequence prevents re-cutting of the repair template after incorporation into the RBM8A 
locus. A T insertion creates a stop codon as shown. An A/T mutation creates an XhoI 
restriction enzyme site for screening purposes. (C) Approximate locations of the PCR 
screening primers are shown. The 733 bp PCR product is digested with XhoI restriction 
enzyme. If the oligo repair template is successfully integrated into the RBM8A locus, the 
PCR product will be digested into 579 bp and 154 bp fragments.  
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CHAPTER 3 
Factor V Uptake as a Marker of Mature Human Stem Cell-derived Megakaryocytes 
 
3.1 Introduction 
The first report of in vitro-generated platelets59 raised the possibility that stem cell-
derived platelets may be produced to complement or displace donor-derived platelets 
clinically.125–127 Although considerable progress has been made in the generation of 
platelets from HSCs,92–94 ESCs and iPSCs,87–89,91,128 there remain important challenges 
to overcome before we can realize the goal of transfusing stem cell-derived platelets into 
humans. Low platelet yield and poor functionality have been important challenges in the 
field.129–132 In part, these unresolved challenges stem from gaps in a detailed 
understanding of MK maturation in vitro, including defining the mature MKs that are 
optimally primed to release platelets and directing cultured MKs to this stage.  
 
MK maturation is accompanied by an increase in cell size, ploidy, granular components, 
MK-specific surface receptors, and the formation of an IMS. 33,35,36,133,134 Whether these 
changes occur sequentially or as a continuum is unclear as is a definition of a mature 
MK that is primed for thrombopoiesis.  
 
Human bone marrow MKs have been classified into 4 developmental stages based on 
size and ploidy: stage I MKs are 10-15 µm (2N/4N), stage II MKs are 14-20 µm (4N/8N), 
and stage III/IV MKs are 20-40 µm (8N-128N).135 The ultrastructural features at these 
stages have been described qualitatively using electron micrographs of primary human 
bone marrow MKs, but these MKs differ greatly from the in vitro-generated MKs, which 
are significantly smaller and with a ploidy that rarely exceeds 16N.25,136 The gene 
expression profiles of MKs of different ploidy have been compared,45,46 but gave little 
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insights into what defines a mature MK primed for thrombopoiesis when infused into a 
bioreactor102,103,137 or into mice.113,138 We hypothesize that there may be a transient stage 
of MK development that is highly efficient in undergoing thrombopoiesis and that 
selective harvesting and/or optimizing the yield of these MKs may enhance functional 
platelet yield. 
 
We examined cell size and granularity changes during human MK differentiation in vitro 
and identified discrete MK maturation stages with distinct granularity, which we termed 
the low granular (LG) and high granular (HG) MKs. We further demonstrated that the 
immature LG MKs give rise to mature HG MKs, which are subdivided into a functional 
CD42b+ population that produces platelets in vitro and after infusion into 
immunodeficient mice, and an apoptotic, non-functional CD42b- population. Moreover, 
using a labeled coagulation factor V (FV) variant, we showed that the HG/CD42b+ MKs 
endocytose FV into alpha-granules and release functional platelets with similar size 
distribution as human donor platelets. Additionally, treatment of MKs with a pan-caspase 
inhibitor, Q-VD-Oph, prevented both apoptosis and CD42b shedding, and enriched the 
functional FV+/CD42b+ population. These studies further our understanding of 
megakaryopoiesis and thrombopoiesis and may have implications for optimizing the 
production of stem cell-derived platelets for transfusion. 
 
3.2 Results 
3.2.1 Identification of Distinct MK Populations During In Vitro Megakaryopoiesis 
Identification of the mature, platelet-producing MKs within the heterogeneous, 
asynchronous MK culture would allow us to find novel ways of improving the yield and 
quality of stem cell-derived platelets. Thus, one goal is to determine if we can identify 
distinct maturation intermediates within the MK culture and if there is a specific 
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maturation intermediate that is primed for thrombopoiesis. Key changes associated with 
MK maturation include: increase in cell size, ploidy, alpha-granule content, RNA and the 
formation of an IMS.33,35,36,133,134 These features lead to increased size and internal 
cellular complexity, which can be detected as increased forward scatter (FSC) and side 
scatter/granularity (SSC) respectively by flow cytometry. By examining these two 
parameters during the differentiation of human CD34+ HPCs into MKs, we identified two 
MK populations distinguishable by their granularity, LG and HG MKs (Figure 3.1A). We 
hypothesize that these novel MK populations represent distinct developmental stages.  
 
The LG MKs appeared around day 7, followed by HG MKs around day 10, with their 
percentage changing over time (Figure 3.1A). Since HG MKs appeared later and had 
high granularity suggestive of cytoplasmic changes associated with maturation, we 
hypothesized that the LG MKs give rise to HG MKs. We tested this hypothesis by sorting 
LG and HG MKs and examined how the granularity of these sorted populations changed 
with further culture. We found that the LG MKs became HG MKs upon further culture 
(Figure 3.1B, top), while the HG MKs remained high granular (Figure 3.1B, bottom), 
confirming that HG MKs came from LG MKs. 
 
3.2.2 A Subpopulation of HG MKs Show Signs of Injury 
We further characterized these two MK populations by examining a panel of known MK 
markers. We found surface CD42b is selectively lost from the HG population, but not the 
LG population (Figure 3.2A). These data further divided the cells into 3 subpopulations: 
LG MKs, HG/CD42b+ MKs and HG/CD42b- MKs. On platelets, the loss of surface CD42b 
is due to metalloproteinase cleavage of the extracellular glycocalicin domain of 
CD42b,139,140 and is associated with platelet activation, apoptosis and clearance.140–144 
We predict that CD42b shedding on HG MKs also signaled damage, thus we examined 
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the MKs for signs of apoptosis. Indeed, 80-90% of the HG/CD42b- MKs were Annexin V+ 
and positive for terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL+) 
(Figure 3.2B), indicating that these cells were apoptotic. In contrast, <20% of the LG 
MKs and HG/CD42b+ MKs were apoptotic (Figure 3.2B). Over time, the percentage of 
LG MKs and HG/CD42b+ MKs decreased gradually with a concomitant accumulation of 
apoptotic HG/CD42b- MKs (Figure 3.2C), suggesting a progression of viable MKs to a 
non-physiological terminal state that would likely decrease in vitro platelet yield.  
 
As LG MKs progressed to HG/CD42b+ MKs, we observe an increase in ploidy (Figure 
3.2D) and some alpha-granule proteins (Figure 3.2E), most notably platelet factor 4 
(PF4), a known MK maturation marker.145 In contrast, HG/CD42b- MKs lost alpha-
granule proteins and most of its RNA content (Figure 3.2E), consistent with their 
transition to a damaged state.  
 
A feature of mature MKs is their ability to respond to platelet agonists.146 To assess the 
responsiveness of these MK subpopulations, we analyzed the percentage of activated 
MKs following stimulation with platelet agonists, convulxin147 or protease-activated 
receptor 1 (PAR1)-activating peptide.148 Activation causes conformational changes in the 
surface glycoprotein IIb/IIIa, detectable by PAC-1 antibody.110,111 While 70-80% of 
HG/CD42b+ MKs activated in response to stimulation, only 20-30% of LG MKs and 
virtually none of apoptotic HG/CD42b- MKs responded (Figure 3.2F). These data 
suggested that HG/CD42b+ MKs may be nearing their peak of maturation and that 
CD42b shedding indicated an undesirable decline of these mature MKs to an apoptotic, 
non-functional state.  
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To determine if these distinct MK populations are present in the human bone marrow, 
we examined the size and granularity of primary MKs from marrow aspirates. Primary 
MKs form a continuum of maturing MKs with increasing cell size and granularity (Figure 
3.3A). Since surface CD42a and CD42b are known to increase with maturation, we 
compared the size and granularity of CD42ahighCD42bhigh MKs and CD42alowCD42blow 
MKs. We observed that the mature CD42ahighCD42bhigh MKs in the bone marrow were 
both larger and more granular than CD42alowCD42blow MKs (Figure 3.3B, top). In 
contrast, the cultured CD42ahighCD42bhigh MKs were more granular, but not bigger than 
the CD42alowCD42blow MKs (Figure 3.3B, bottom). We also did not detect the presence 
of CD42a+CD42b- MKs in bone marrow (Figure 3.3A). These differences between 
marrow MKs and cultured MKs will be further discussed.  
 
3.2.3 FV Uptake Labels Mature, Undamaged MKs 
Human coagulation FV is synthesized by the liver and circulates in the plasma.149,150 
While mouse MKs produce FV endogenously151, human MKs endocytose FV from their 
surroundings and package it into alpha-granules.42,152–154 However, the specific stage of 
maturation when human MKs endocytose FV is unknown.155 The HG/CD42b+ MKs have 
many characteristics of mature MKs and may be the population that is primed to release 
platelets. We hypothesized that the HG/CD42b+ MKs may be able to endocytose FV and 
that FV uptake may be a marker of fully mature MKs.  
 
A putative receptor for FV endocytosis is the low-density lipoprotein receptor related 
protein 1 (LRP1),156 which is upregulated on the surface of mature MKs.157 HG/CD42b+ 
MKs showed higher surface LRP1 expression as compared to LG MKs (Figure 3.4A). FV 
uptake by MKs, as assayed by pulse-labeling MKs with a fluorescently-labeled FV 
variant,120 correlated with ploidy, suggesting that FV endocytosis increased with 
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maturation (Figure 3.4B). Correspondingly, the HG/CD42b+ MKs endocytose more FV 
than the LG MKs (Figure 3.4C). To determine if the kinetics of FV endocytosis change 
over time, we pulse-labeled MKs with fluorescently-labeled FV on days 11 and 15 of the 
differentiation. On day 11, LG MKs showed negligible FV uptake while HG/CD42b+ 
exhibited greater FV uptake (Figure 3.4C). By day 15, both MK populations matured 
over time and took up FV, but the HG/CD42b+ MKs still endocytosed FV more efficiently 
than the LG MKs.  
 
To correlate FV uptake with gene expression changes during MK maturation, we sorted 
CD42blow/FV- MKs, CD42bhigh/FV- MKs and CD42bhigh/FV+ MKs (Figure 3.4D) and 
compared the expression of MK maturation genes in these populations. CD42blow/FV- 
MKs correspond to LG MKs, while CD42bhigh/FV- MKs correspond to the smaller 
HG/CD42b+ MKs and CD42bhigh/FV+ MKs correspond to the larger HG/CD42b+ MKs 
(Figure 3.4E), consistent with FV uptake being a marker of mature MKs. We found that 
the expression of MK maturation genes peak as MKs gain CD42b, with little or no 
increase as MKs acquire the ability to endocytose FV (Figure 3.4F). These data suggest 
that the ability to endocytose FV is only acquired in the most mature MKs with peak 
expression of known MK maturation markers, indicating that FV uptake could be one of 
the final markers of a fully mature MK primed for thrombopoiesis.  
 
To determine if FV localized to the alpha-granules following endocytosis, we performed 
immunofluorescence studies on FV-labeled MKs, co-staining for the MK surface marker 
(CD41 or CD42b) and an alpha-granule marker (von willebrand factor (VWF)). CD42b+ 
MKs showed a punctate distribution of intracellular FV, which partially co-localized with 
VWF in granules (Figure 3.5A). In contrast, we observed that CD42b- MKs were 
associated with a very high level of FV fluorescence distinctly localized to the cell 
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surface (Figure 3.5B-C). We believe that this was due to FV binding to 
phosphatidylserine (PS) on the surface of apoptotic MKs.120  
 
To confirm that the damaged HG/CD42b- MKs came from the HG/CD42b+ population, 
we pulse-labeled MKs on day 11, when all the HG MKs are CD42b+. Forty-eight hours 
later, the newly generated HG/CD42b- MKs had the same level of FV fluorescence as 
the HG/CD42b+ MKs post-labeling (Figure 3.5D), indicating that the HG/CD42b- MKs 
came from the HG/CD42b+ population and that prevention of this damage may enhance 
platelet yield.  
 
3.2.4 FV-Labeled MKs Release Platelets When Infused into Immunodeficient Mice 
To determine if FV-labeled HG/CD42b+ MKs preferentially generated functional platelets 
in vivo, we infused FV-labeled MKs into NSG mice. We previously demonstrated that 
human donor platelets infused into NSG mice could be detected in the blood and were 
~10-fold larger than mouse platelets.113 When cultured human MKs were infused into 
NSG mice, we observed two distinct populations of human platelet events: (1) platelet-
like particles (PLPs) with a broad size-range that have limited half-life and functionality, 
and (2) platelets released from pulmonary-entrapped MKs that have similar size 
distribution, half-life and functionality as donor platelets.113 These data suggest that size 
can be used as a discriminatory factor to examine if the human platelet events detected 
in the circulation are more like non-functional PLPs or functional platelets.  
 
For these studies, we used day 11 MKs to avoid the HG/CD42b- subpopulation that 
accumulates over time and binds FV non-specifically (Figure 3.2C and Figure 3.5B-C). 
Following the infusion of FV-labeled MKs, we detected both FV+ and FV- human platelet 
events in the circulation post-infusion (Figure 3.6A-B). We observed that all FV+ platelet 
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events were MK-derived platelets, with sizes similar or larger than donor platelets, as 
early as 5 minutes post-infusion and at all time points following (Figure 3.6C-E). In 
contrast, the FV- platelet events had a broad range of sizes initially, indicating that they 
were a mixture of PLPs and MK-derived platelets, but by 1-4 hours, the short-lived PLPs 
were cleared, leaving mostly the MK-derived platelets in circulation (Figure 3.6C-E). 
These data suggest that although both FV+ and FV- MKs release platelets, FV+ MKs 
appear primed to release platelets as soon as they encounter the right in vivo 
environment. 
 
3.2.5 FV+ Platelets Are Incorporated into Thrombi Following Laser Injury 
To examine the functionality of FV+ platelets, we performed laser injury studies following 
the infusion of MKs double-labeled with FV-Alexa-488 and calcein red-orange. To 
visualize the clot, we labeled mouse platelets with mCD41-Alexa-647 (blue). We 
detected both FV+ (yellow) and FV- (red) human platelets/PLPs in the clots (Figure 3.7A). 
Given that the MKs infused were 33 ± 3% FV+ and the circulating platelets/PLPs were 29 
± 2% FV+, the observation that FV+ particles were present at 74 ± 6% in the clot (Figure 
3.7B-C) support that FV+ platelets were preferentially incorporated over FV- particles, 
suggesting that FV+ platelets had better functionality than FV- platelets/PLPs.  
 
3.2.6 FV-Labeled MKs Generate FV-Labeled PLPs In Vitro That Are Partially 
Functional  
To determine whether FV-labeled MKs generate FV-labeled PLPs in vitro, we analyzed 
in vitro PLPs from day 11 FV-labeled MKs 24 hours post-labeling. All CD42b+ PLPs in 
vitro were FV-labeled (Figure 3.8A), indicating that they came from FV-labeled 
HG/CD42b+ MKs. There was a small but distinct subpopulation of CD42b- PLPs that 
were FVhigh (Figure 3.8A), which likely came from apoptotic HG/CD42b- MKs that bind FV 
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through their surface PS. Consistent with published data,89,158 the FV-labeled CD42b+ 
PLPs were slightly larger than human donor platelets (Figure 3.8B). The FV-labeled 
CD42b+ platelets were Annexin Vlow and activated in response to agonist stimulation, 
although not as well as human donor platelets (Figures 3.8C-E), suggesting that they are 
partially functional. In contrast, the CD42b- PLPs were smaller than donor platelets, 
Annexin Vhigh and did not respond to agonist stimulation (Figures 3.8B-E), indicating that 
they are likely non-functional cellular debris.  
 
3.2.7 Metalloproteinase Inhibition Protects MKs From CD42b Shedding, but Not 
Apoptosis  
Metalloproteinase cleavage of CD42b on platelets occurs following activation, apoptosis 
or improper storage,141–144,159 thus CD42b surface expression is a key parameter for 
assessing platelet quality. Metalloproteinase inhibitors like GM6001 prevent CD42b 
shedding on platelets and improve the hemostatic function and recovery of platelets 
post-infusion.139 These drugs have also been used to protect in vitro-generated platelets 
from damage.90,160 Since CD42b shedding and apoptosis are intricately linked events in 
platelets and the regulation of apoptosis in MKs is crucial for platelet formation, we 
examined whether inhibiting CD42b shedding can enrich the HG/CD42b+ subpopulation.  
 
Treatment of MKs with GM6001 preserved CD42b expression, but did not affect 
apoptosis (Figures 3.9A-B). Importantly, although the percentage of CD42b+ MKs 
increased following treatment, many of these MKs remained apoptotic and fewer 
CD42b+ MKs responded to agonist stimulation (Figure 3.9C), indicating that the 
preservation of CD42b on MKs is insufficient to preserve MK viability.  
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3.2.8 Apoptosis Inhibition Protects MKs From Both Apoptosis and CD42b 
Shedding 
To examine whether apoptosis inhibition can enrich the HG/CD42b+ subpopulation, we 
treated MKs with a pan-caspase inhibitor, Q-VD-Oph.161,162 Q-VD-Oph inhibited both 
apoptosis and CD42b shedding (Figure 3.10A), resulting in a 90% reduction in the 
percentage of apoptotic CD42b- MKs and a 50% increase in the percentage of CD42b+ 
MKs (Figure 3.10B). More specifically, Q-VD-Oph enriched the HG/CD42b+ MKs (Figure 
3.10C). These data suggested that CD42b shedding occurred downstream of apoptosis. 
To determine if Q-VD-Oph affected the localization of ADAM17, the metalloproteinase 
responsible for CD42b shedding,140 we analyzed ADAM17 surface expression on MKs. 
We found that ADAM17 surface expression was upregulated with maturation and was 
unaffected by Q-VD-Oph (Figure 3.10D). However, the ADAM17’s activity require PS 
exposure,163 thus ADAM17 is poised to cleave CD42b on mature MKs, but is unable to 
do so unless PS is exposed following apoptosis. This also explains why CD42b 
shedding occurs only on HG MKs, but not on LG MKs. Therefore, we posit that by 
inhibiting apoptosis and PS exposure, Q-VD-Oph also prevents CD42b shedding.  
 
Importantly, apoptosis inhibition by Q-VD-Oph did not affect ploidy or responsiveness to 
agonists (Figure 3.10E-F) and led to a small increase in FV uptake by the HG/CD42b+ 
MKs (Figure 3.10G). When Q-VD-Oph-treated MKs were infused into NSG mice, we 
detected increased number of human platelets post-infusion (Figure 3.10H). However, 
Q-VD-Oph treatment led to a decrease in the yield of CD42b+ PLPs in vitro (Figure 
3.10I).  
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3.2.9 Distinct MK Populations Can Also Be Found in iPSC-Derived MK Cultures 
To determine whether these MK subpopulations were present in MK cultures derived 
from a different stem cell source, studies were repeated with human iPSC-derived MKs. 
LG, HG/CD42b+ and HG/CD42b- MK populations were present within iPSC-derived MK 
cultures (Figure 3.11A-B). Similarly, HG/CD42b+ MKs endocytosed more FV than LG 
MKs (Figure 3.11C). When we inhibited apoptosis with Q-VD-Oph, iPSC-derived MKs 
showed decreased apoptosis and CD42b shedding (Figure 3.11D). Thus, these distinct 
MK maturation stages are present in MK cultures derived from two different stem cell 
sources.  
 
3.3 Discussion 
Despite advances in the understanding of megakaryopoiesis and thrombopoiesis, it 
remains unclear what defines a MK that is primed to release platelets. Our studies 
addressed this important question through developmental staging of human stem cell-
derived MKs beginning with the idea that MKs increase in size and granularity with 
maturation.133 We identified distinct stages of MK differentiation with an initial maturation 
phase leading to a transient, functional stage, followed by a declining phase 
characterized by apoptosis, CD42b shedding and a loss of RNA and alpha-granule 
proteins (Figure 3.12). These stages are not clearly distinguishable in primary marrow 
MKs as mature MKs exit the marrow to shed platelets in the circulation,54 thus, normally 
few or no MKs undergo apoptosis and/or CD42b shedding in the marrow. These insults 
may be more apparent in clinical settings like myelodysplastic syndromes and immune 
thrombocytopenia purpura, where intramedullary MKs fail to exit the marrow and/or 
undergo apoptosis.164–167 The loss of RNA and alpha-granule proteins may be due to 
degranulation, typically observed in idiopathic myelofibrosis, where growth factors 
released from MK alpha-granules promote marrow fibrosis.168–170 Collectively, apoptosis, 
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CD42b shedding and degranulation are associated with pathological clinical outcomes, 
suggesting that protecting cultured MKs from such insults may be important for 
producing high quality stem cell-derived platelets. Additionally, while primary marrow 
MKs increase in size and granularity as they mature, in vitro-derived MKs increase in 
granularity, but not in size as they mature. This result correlates with published 
observations that cultured MKs do not achieve high ploidy like those in vivo,25,133,136 
reiterating the idea that the size and ploidy of in vitro-grown MKs may limit platelet 
yields. 
 
Unlike murine MKs, which express FV endogenously151, human MKs endocytose FV 
from the surroundings. We examined if the FV uptake into alpha-granules would be a 
useful marker of mature, functional human MKs. When we pulse-labeled the 
heterogeneous MK culture with fluorescently-labeled FV, the mature HG/CD42b+ MKs 
preferentially internalized the FV. The FV+ MKs released functional platelets with a size 
range similar or larger than human donor platelets almost immediately post-infusion. 
Since newly released young platelets and pre-platelets are larger than circulating old 
platelets,158,171,172 FV+ platelets are likely young platelets released in vivo by infused FV-
labeled MKs. Moreover, FV+ platelets are overrepresented in clots following laser injury, 
an indication of better functionality over FV- platelets. Additionally, all functional, CD42b+ 
in vitro PLPs are derived from the FV+ MKs, reaffirming that FV+ MKs are primed for 
platelet formation. With these new insights into the specific stage of MK maturation when 
FV endocytosis occurs, we can use this model to address the mechanisms of FV 
endocytosis and trafficking in human MKs, which is critical as mouse models do not 
accurately reflect human physiology in regard to FV uptake. 
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The heterogeneous and asynchronous nature of MK cultures makes it difficult to purify 
the mature MKs that are primed for platelet production. To improve the efficiency of in 
vitro platelet generation, we propose that FV labeling could be a tool to harvest the 
transient, mature MKs for platelet bioreactor use102,103,137, particularly since MK’s ability 
to endocytose FV is acquired after peak expression of many maturation genes. 
Genome-wide studies to compare CD42bhigh/FV- and CD42bhigh/FV+ MKs may lead to the 
identification of novel MK maturation markers, potentially cell surface receptors that 
could be useful substitutes for FV for the purification of mature MKs. Alternatively, FV+ 
MKs may be infused into patients with the anticipation that they would release a large 
number of platelets rapidly after infusion. Apart from FV, MKs also endocytose other 
proteins like fibrinogen43,52,173 and immunoglobulins.51 Whether endocytosis of these 
proteins by MKs occurs at the same stage of maturation and whether they could 
substitute for FV uptake is presently unclear.  
 
We also found that CD42b shedding occurs downstream of apoptosis, likely due to 
ADAM17 activation by exposed PS on the MK following apoptosis, thus apoptosis 
inhibition also prevented CD42b shedding and enriched the mature FV-labeled MKs. 
The role of apoptosis in platelet formation is controversial.174 Initial studies supporting 
the requirement of apoptosis in platelet formation showed that caspase inhibition 
blocked proplatelet formation in culture and that compartmentalized activation of 
caspases is necessary for cytoskeletal rearrangements during platelet shedding.175,176 
However, later studies showed that mice deficient in various components of the intrinsic 
and extrinsic apoptotic pathways shed platelets normally.177,178 In fact, apoptosis 
regulation is crucial for keeping MKs alive during platelet formation.179 We observed 
increased in vivo platelet yield following infusion of Q-VD-Oph-treated MKs, but 
decreased in vitro yield of PLPs from the same MKs. This may be due to differences in 
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platelet formation in vitro and in vivo. It is tempting to speculate that in vitro PLPs may 
arise through an apoptotic-related process while platelet formation in vivo occurs through 
a different mechanism. Future studies examining in vitro and in vivo platelet formation 
from human MKs deficient in various components of the apoptotic pathways may shed 
more light on the relationship between survival, apoptosis and platelet formation.  
 
In conclusion, we have identified distinct maturation stages within the in vitro MK culture. 
Within these stages, a transient, mature, functional HG/CD42b+ MK population becomes 
damaged and apoptotic over time. MKs at peak maturation endocytose FV, and this 
ability to endocytose FV correlates with readiness to release functional platelets when 
infused into immunodeficient mice. Additionally, we found that apoptosis inhibition 
protects the mature, platelet-producing MKs and results in increased platelet yield in 
vivo, but not in vitro. These studies provide new insights into megakaryopoiesis and 
thrombopoiesis, and offer new tools that may be beneficial for improving platelet 
production from cultured MKs and to study human-specific MK physiology.  
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Figure 3.1 
 
Figure 3.1. Two MK Populations with Distinct Granularity are Present in the In 
Vitro Human Stem Cell-derived MK Culture Representative size (FSC-A) and 
granularity (SSC-A) profiles of CD42a+ MKs at specified time points during the 
differentiation of human CD34+ hematopoietic progenitors. LG and HG MKs are gated as 
shown. (B) (Top) Day 14 LG CD42a+ MKs were sorted and cultured for another 6 days. 
Size and granularity of MKs 3 days and 6 days post-sort are shown. (Bottom) Day 14 
HG CD42a+ MKs were similarly sorted and cultured. Profiles shown are representative of 
three independent studies. 
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Figure 3.2 
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Figure 3.2. HG/CD42b+ MKs Have Characteristics of Mature MKs (A) Representative 
flow plots of CD42b expression on LG (green) and HG (red) MKs at specified time points 
of the differentiation. (B) Representative flow plots of Annexin V staining (left) and 
TUNEL staining (right) on day 14 MK cultures. (C) The percentage ± 1 SEM for each MK 
subpopulation at specified time points of the differentiation are shown of four 
independent studies. (D) Graph quantifying the percentages of MKs in each ploidy class 
± 1 SEM of five independent studies. (E) Expression of alpha-granule proteins (bFGF, 
VEGF, PF4, Col18A) and total RNA content of day 14 MKs were determined by 
intracellular staining and TO staining, respectively. Graphs quantifying the fold changes 
in mean fluorescence intensity over isotype/background ± 1 SEM are shown.  (F) Day 14 
MKs were stimulated with convulxin (500 ng/ml) or PAR-1-activating peptide (50 µM) for 
20 minutes at RT. (Top) Representative flow plots showing percentages of activated 
(PAC-1+) MKs following convulxin stimulation. Black dotted line histogram indicates 
background staining in the absence of stimulation. (Bottom) Graph quantifying the 
percentages of PAC-1+ MKs following convulxin or PAR-1-activating peptide stimulation 
(n = 5 independent studies). * p < 0.05, ** p < 0.01, *** p < 0.005, *** p < 0.001 for all 
statistical analyses shown. p values are determined by the student’s t test.  
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Figure 3.3 
 
 
Figure 3.3. Primary Human Bone Marrow MKs Increase in Size and Granularity as 
They Mature (A) Human bone marrow aspirates were processed through a Percoll 
density gradient and subjected to red cell lysis treatment before staining for CD42a and 
CD42b. (Left) Percentage of CD42a+CD42b+ MKs detected in the processed human 
bone marrow aspirate. (Right) Size and granularity of CD42a+CD42b+ bone marrow MKs.  
(B) Representative size and granularity profiles of CD42alowCD42blow (blue) and 
CD42ahighCD42bhigh (red) MKs from human bone marrow and from cultured CD34+ 
hematopoietic progenitors. Profiles are representative of three independent studies. 
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Figure 3.4 
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Figure 3.4. FV Uptake Correlates with Maturation (A) Surface expression of LRP1 
receptor on day 14 MKs. (Left) Representative flow plot of LRP1 surface expression on 
LG and HG/CD42b+ MKs. (Right) Graph quantifying median fluorescence intensity of 
LRP1 expression over isotype for LG and HG/CD42b+ MKs. Mean ± 1 SEM are shown 
(n = 5 independent studies). (B) Day 14 MKs were pulse labeled with 200 nM FV-Alexa-
488 or Alexa-647 for 1 hour at 37°C. (Left) Representative flow plot of FV uptake by 
CD42b+ MKs of different ploidy classes. (Right) Graph quantifying median FV 
fluorescence over background associated with MKs of different ploidy classes (n = 4 
independent studies). (C) Day 11 or day 15 MKs pulse labeled with FV as in (B). (Left) 
Representative flow plot of FV uptake by LG and HG/CD42b+ MK populations are 
shown. (Right) Graph quantifying median FV fluorescence over background associated 
with LG and HG/CD42b+ MKs on days 11 and 15. (D) Day 11 or 14 MKs were pulse-
labeled with 200 nM of FV-Alexa-647 for 1 hour and stained with CD42b-PE antibody for 
20 minutes at 37°C and washed twice prior to sorting. (Left) Representative plots of 
CD42b expression and FV fluorescence of unlabeled (blank) and labeled (pre-sort) MKs 
prior to sorting. Three populations were sorted for comparison: CD42blow/FV-, 
CD42bhigh/FV- and CD42bhigh/FV+. (Right) Representative plots of CD42b expression and 
FV fluorescence of sorted populations of 4 independent studies. (E) Representative 
FSC-A (size) and SSC-A (granularity) profiles of sorted populations. (n = 4) (F) 
Expression of late MK markers were examined in sorted MKs from (D) by qPCR. mRNA 
expression of late MK markers (PF4, VWF, C-MYC, NFE2 (nuclear factor, erythroid 2), 
TUBB1 (Tubulin Beta 1), GATA1 (Gata binding protein 1)) relative to housekeeping gene 
TBP in sorted CD42blow, CD42bhigh/FV- and CD42bhigh/FV+ populations are shown. * p < 
0.05, ** p < 0.01, *** p < 0.005, *** p < 0.001 for all statistical analyses. p values are 
determined by the student’s t test. 
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Figure 3.5 
 
Figure 3.5. Mature MKs Endocytose FV into Their Alpha-granules (A) 
Immunostaining of CD42b and VWF was performed on day 14 FV-labeled MKs that 
were adhered to fibronectin-coated glass cover slips. Confocal images of the MKs show 
FV colocalizing with VWF in alpha-granules. Images were acquired using a DMi8 
microscope (Leica Biosystems) equipped with a 63x Plan Apochromat objective (1.4NA) 
and a Hamamatsu Photonics ORCA-Flash4.0 sCMOS digital camera. (B) Day 14 MKs 
were pulse labeled with 200 nM of FV-Alexa-488 for 1 hour at 37°C. Representative flow 
plots showing the FV fluorescence associated with each MK subpopulation. (C) FV-
labeled MKs were immunostained with VWF and CD42b. CD42b+ MKs showed punctate 
staining of intracellular FV, which colocalized with alpha-granule marker VWF, while 
CD42b- MKs showed surface staining of FV. (D) Day 11 MKs were pulse labeled with FV 
as in (B). Excess FV was removed by washing, and MKs were followed for 48 hours. 
Representative flow plot showing that the intensity of FV fluorescence associated with 
HG/CD42b+ MKs 1 hour post-labeling is the same as that associated with HG/CD42b- 
MKs 48 hours later, indicating that HG/CD42b+ MKs give rise to HG/CD42b- MKs.  
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Figure 3.6 
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Figure 3.6. FV-labeled MKs Generate FV+ Platelets in the Circulation of NSG Mice 
Post-infusion Day 11/12 MKs were incubated with 200 nM FV-Alexa-488 for 1 hour at 
37°C prior to infusion into NSG mice. (A) Representative flow plots showing the FV 
fluorescence of CD42a+CD42b+ human platelet events detected in the circulation at the 
specified time points post-infusion. Percentages of FV+ platelet events are displayed. (B) 
Graph quantifying the percentage of CD42a+ CD42b+ FV+ human platelet events in the 
circulation over time post-infusion. Mean ± 1 SEM are shown for 4 independent studies. 
(C) Representative flow plots showing the sizes of CD42a+CD42b+ FV+ (red) and FV- 
(black) human platelet events detected in the circulation of mice at the specified time 
points after the infusion of FV-labeled MKs. The sizes of mouse platelets are shown in 
grey. (D) (Left) Relative sizes of endogenous mouse platelets and infused human donor 
platelets. Platelets were considered large if their FSC-As are larger than 90% of the 
mouse platelets’ FSC-As. (Right) Percentage of FV+ (red) and FV- (black) platelets that 
were large at the various time points post-infusion. Mean ± 1 SEM are shown. (n = 4) *** 
p < 0.005, as determined by the student’s t test. (E) Graph showing the relative sizes of 
FV+ and FV- platelets over time. Mean ± 1 SEM are displayed for 4 independent studies. 
The size ranges of infused human donor platelets (orange) and mouse platelets (grey) 
are shown for comparison.  
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Figure 3.7 
 
Figure 3.7. FV+ MKs Release Functional FV+ Platelets In Vivo (A) Day 11 MKs 
double-labeled with calcein red orange (red) and FV-Alexa-488 (green) were infused into 
NSG mice 30 minutes prior to the induction of the first cremaster arteriole laser injury. 
Representative confocal images of clots formed after laser injury are shown. Mouse 
platelets are labeled with CD41-Alexa-647 (blue). All human platelets derived from 
infused MKs are calcein-labeled (red). FV-labeled (green) human platelets appear yellow 
in the overlay. Scale bars shown are 10 µm. (B) Representative flow plots showing the 
percentage of FV-labeled MKs that were infused (left) and FV-labeled human platelets 
circulating in mice post-infusion (right). (C) Quantification of the percentages of FV-
labeled MKs that were infused with 5 independent studies, FV-labeled human platelets 
detected in the circulation post-infusion (n=4) and FV-labeled platelets detected in the 
clot (n = 25). *p < 0.05, ** p < 0.01, *** p < 0.005 for all statistical analyses. p values are 
determined by the student’s t test. 
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Figure 3.8 
Figure 3.8. FV-labeled MKs Give Rise to Functional CD42b+ Platelets In Vitro Day 
11 MKs were pulse labeled with FV, washed and resuspended in fresh medium. In vitro 
platelets were harvested 24 hours later for analysis. (A) CD42b and FV expression of 
CD42a+ platelet-sized particles harvested from non-labeled (left) and FV-labeled (right) 
MKs. CD42b+FV+, CD42b- FVhigh and CD42b- particles were gated as shown. (B) 
Relative sizes of platelet-sized particles in vitro compared to human donor platelets. (C) 
Quantification of Annexin V staining on platelet-sized particles in vitro compared to 
human donor platelets. (D) In vitro platelets and human donor platelets are stimulated 
with PAR1-activating peptide (25 µM) for 20 minutes at 37°C. Platelet activation is 
indicated by the increase in surface CD62P expression. (E) Graph quantifying the fold 
change in CD62P expression over baseline when in vitro platelet-sized particles and 
human donor platelets are stimulated.  
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Figure 3.9 
 
Figure 3.9. Effect of Metalloproteinase Inhibition on MKs. MKs were treated with 
GM6001 (100 µM) or DMSO (control) from day 8 to day 15 and analyzed on day 15. (A) 
Representative flow plots showing CD42b expression versus Annexin V binding or 
TUNEL positivity in MKs treated with GM6001 or DMSO.  (n = 5) (B) Graph quantifying 
the fold changes in the percentages of MK subpopulations with GM6001 treatment 
relative to DMSO. Mean ± 1 SEM is shown. (n ≥ 3) (C) Quantification of the percentages 
of CD42b+ MKs that are PAC-1+ after convulxin (left) or PAR1-peptide (right) activation 
of GM6001 or DMSO treated MKs. Mean ± 1 SEM is shown for 5 independent studies. 
*p < 0.05, ** p < 0.005, *** p < 0.001 for all statistical analyses. p values are determined 
by the student’s t test. 
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Figure 3.10. Effect of Apoptosis Inhibition on MKs and Platelet Production MKs 
were treated with Q-VD-Oph (25 µM) or DMSO (control) from day 8 to day 15 and 
analyzed on day 15. (A) Representative flow plots showing CD42b expression versus 
Annexin V binding or TUNEL positivity in MKs treated with DMSO or Q-VD-Oph. (B) 
Graph quantifying fold changes in the percentages of MK subpopulations with Q-VD-
Oph treatment relative to DMSO. Mean ± 1 SEM are shown for 4 independent studies. 
(C) Quantification of the percentages of MK subpopulations with DMSO or Q-VD-Oph 
treatment. Mean ± 1 SEM are shown for 4 independent studies. (D) Graph quantifying 
the mean fluorescence intensity of ADAM17 expression over isotype on DMSO or Q-VD-
Oph-treated day 15 MKs. Mean ± 1 SEM are shown. (E) Graph quantifying the 
percentages of CD42b+ MKs in each ploidy class with DMSO or Q-VD-Oph treatment. 
Mean ± 1 SEM are shown for 4 independent studies. (F) Quantification of the 
percentages of CD42b+ MKs that are PAC-1+ after convulxin (left) or PAR1-peptide 
(right) activation of DMSO or Q-VD-Oph-treated MKs. Mean ± 1 SEM are shown for 6 
independent studies. n.s. = not significantly different between treatment arms. (G) 
DMSO and Q-VD-Oph treated MKs were pulse labeled with FV. (Left) Representative 
plot showing FV uptake by LG and HG/CD42b+ MKs treated with DMSO or Q-VD-Oph. 
(Right) Quantification of FV uptake by DMSO and Q-VD-Oph treated MKs. Mean ± 1 
SEM are shown for 4 independent studies. (H) Graph quantifying the relative platelet 
production at specified time points following the infusion of Q-VD-Oph or DMSO-treated 
MKs into immunodeficient mice. Platelet production is normalized to DMSO control at 
each time point. Mean ± 1 SEM are shown for 6 independent studies. (I) Graph 
quantifying the relative in vitro platelet yield from DMSO or Q-VD-Oph treated MKs for 5 
independent studies. n.s. = not significantly different between treatments for all statistical 
analyses. *p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.001 for all statistical analyses. p 
values are determined by the student’s t test. 
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Figure 3.11 
Figure 3.11. LG and HG MK Populations Are Present in iPSC-derived MK Cultures 
(A) Representative size and granularity profiles of iPSC-derived CD42a+ MKs at 
specified time points of the differentiation. LG and HG MKs are gated as shown. (B) 
Representative flow plots showing CD42b expression of LG and HG MKs at specified 
time points of the differentiation. (C) Day 4 MKs were incubated with 200 nM of FV-
Alexa-647 for 1 hour at 37°C. (Left) Representative flow plot showing FV uptake by LG 
and HG/CD42b+ MKs. (Right) Graph quantifying FV uptake by LG and HG/CD42b+ MKs.  
Mean ± 1 SEM are shown for 3 independent studies. (D) MKs were treated with Q-VD-
Oph (25 µM) or DMSO from day 4 to day 7 of the differentiation. (Left) Representative 
flow plots showing CD42b expression and Annexin V binding of day 7 MK cultures with 
DMSO or Q-VD-Oph treatment. (Right) Graph quantifying the fold changes in the 
percentages of MK subpopulations with Q-VD-Oph treatment relative to DMSO. Mean ± 
1 SEM are shown for 4 independent studies. * p < 0.05, ** p < 0.01, *** p < 0.005 and 
**** p < 0.001 for all statistical analyses. p values are determined by the student’s t test. 
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Figure 3.12	  	  
 
Figure 3.12.  Developmental Staging of In Vitro-generated MKs Schematic 
representation of the stages as immature human MKs mature and then undergo injury. 
(A) The immature LG MK population has low ploidy and few internal granules and show 
limited response to agonist stimulation. These LG MKs mature to become the 
HG/CD42b+ MK population. (B) The mature HG/CD42b+ MKs have increased ploidy, 
RNA and alpha-granular content as compared to the immature LG MKs. They are also 
maximally responsive to stimulation by various agonists. (C) Mature HG/CD42b+ MKs 
take up fluorescently-labeled FV into their alpha granules and release FV-labeled 
platelets in vitro and in the circulation of mice when infused. The FV-labeled platelets are 
similar in size or larger than human donor platelets. FV-labeled platelets are 
incorporated into clots and activate in response to agonist stimulation, suggesting that 
they are functional. (D) GM6001 inhibits CD42b shedding from MKs, but does not 
prevent apoptosis or improve MK functionality. (E) On the other hand, blocking apoptosis 
also prevents CD42b shedding, and redirects MKs to increase the number of CD42b+ 
MKs that take up FV and release functional platelets. 
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CHAPTER 4 
Elucidating the Disease Mechanism of TAR Syndrome Using Patient-Specific iPSCs 
 
4.1 Introduction  
TAR Syndrome is a rare congenital disorder characterized by low platelet count, bilateral 
absence of the radius bone, other skeletal abnormalities and cardiac lesions. The low 
platelet count in TAR patients is likely due to defects in MK development and maturation 
as 1) TAR patients have severely reduced number of mature MKs in their bone 
marrow71,73 and 2) hematopoietic/MK progenitors isolated from TAR patients show 
defects in the growth of colony-forming units (CFU)-MK and differentiate poorly into MKs 
in vitro.71–73  
 
In 2012, Albers et. al. uncovered the genetic basis of TAR syndrome as the compound 
inheritance of a low frequency SNP with a rare null mutation in the RBM8A gene. The 
null mutation in RBM8A gene in TAR patients is most commonly due to a deletion of at 
least 200 kb in the chromosome region of 1q21.1 while the SNPs are either in the 5’ 
UTR (G/A) or the first intron (G/C) of the intact RBM8A allele. Since the SNPs are in the 
non-coding regions of the protein, a hypomorphic mechanism is proposed, in which the 
loss of one copy of RBM8A (due to the deletion/null mutation) is exacerbated by further 
reductions in RBM8A expression by noncoding SNPs on the remaining copy. Thus, the 
reduction of RBM8A expression below a certain threshold level may be responsible for 
TAR syndrome. RBM8A codes for the Y14 protein, which forms part of the EJC involved 
in enhancing the translation of spliced mRNAs and regulating the nonsense-mediated 
decay of mRNAs with premature stop codons. It remains unclear how suboptimal 
expression of RBM8A, which is ubiquitously expressed in all cells and performs essential 
cellular functions, targets megakaryopoiesis and thrombopoiesis.  
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Investigating the disease mechanism of TAR syndrome has been a challenge due to the 
difficulties in isolating primary MKs from patients, since MKs are very rare in the bone 
marrow and even rarer in TAR patients. With the growing ease of reprogramming patient 
samples to iPSCs and the improvements in differentiation protocols, it is now possible to 
use patient-specific iPSCs as a disease model to study the mechanism of TAR 
syndrome. 
 
We reprogrammed fibroblast and blood samples from TAR patients into iPSCs and 
differentiated iPSCs into HPCs, which can be further differentiated into various 
hematopoietic lineages in colony assays and liquid cultures. We verified that TAR 
patient-specific iPSCs have the genotypes described by Albers et. al. previously and 
also identified a novel 3’ UTR SNP that is also associated with TAR syndrome. We 
found that a clear reduction in RBM8A mRNA expression by at least 50% in TAR 
patient-derived iPSCs and HPCs as compared to wild type (WT). Interestingly, minor 
differences in Y14 protein expression between TAR iPSCs and WT iPSCs are observed.  
 
TAR HPCs showed decreased propensity to form MKs and other hematopoietic colonies 
in colony assays compared to WT, but were able to differentiate normally into MKs and 
erythrocytes in liquid culture. When RBM8A expression is restored in TAR iPSCs using a 
doxycycline-inducible transgene expression system in the AAVS1 safe harbor locus, we 
saw minimal effect on hematopoiesis and megakaryopoiesis, which suggests that 
RBM8A expression in TAR iPSCs may be sufficient for normal primitive hematopoiesis 
and megakaryopoiesis. Thus to determine if RBM8A plays any role in 
hematopoiesis/megakaryopoiesis, we went further to knock out RBM8A completely in 
iPSCs and found that complete deficiency of RBM8A is lethal for iPSCs as well as all 
differentiated hematopoietic lineages.  
	  	  	   72 
Overall, we were able to recapitulate a partial phenotype of TAR syndrome in vitro using 
patient-derived iPSCs and demonstrate that a basal level of RBM8A expression is 
necessary for the survival of all cell types. Unfortunately, the mystery of whether and 
how RBM8A/Y14 contribute to the disease pathogenesis of TAR syndrome remained 
unresolved. The limitations of our current differentiation system in elucidating the 
disease mechanism of TAR syndrome and how we can address these limitations are 
discussed.  
 
4.2 Results 
4.2.1 TAR Syndrome Patient-Specific iPSCs Carry a Deletion in the Chromosome 
Region 1q21.1 and a SNP in the 5’ or 3’ UTR of the RBM8A Gene 
Most TAR patients have a minimum deletion of 200 kb in the chromosome region 
1q21.1, which results in the loss of 1 copy of the RBM8A gene.75,76 They also have a low 
frequency SNP in the 5’ UTR (G/A) or first intron (G/C) of the intact RBM8A allele.75 To 
verify that the TAR patient-derived iPSCs have these genetic characteristics, we 
performed copy number variance analysis and sequencing on genomic DNA isolated 
from TAR iPSCs and various control iPSCs from patient’s family members and unrelated 
WT individuals.  
 
All TAR iPSCs (TAR1, TAR2 and TAR128) from 3 different TAR patients carry the 
1q21.1 deletion, with TAR 128 having the biggest deletion in the region (Figure 4.1A). 
CTL2, reprogrammed from the sister of TAR2, and CTL129, reprogrammed from the 
mother of TAR128, carry the same deletion as the patients, but these family members 
are not affected with TAR syndrome because they do not have the disease-associated 
SNPs (Figure 4.1A and B). TAR1 and TAR2 iPSC lines have the (G/A) 5’ UTR SNP 
associated with TAR syndrome (Figure 4.1B).  Interestingly, instead of the 5’ UTR or first 
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intronic SNP, TAR128 has a (C/G) SNP in the 3’ UTR, 6 nucleotides from the stop 
codon, which is the prevalent SNP in the African American TAR patient population (V. 
Horner, personal communication). A summary of the genotypes of the iPSC lines and 
who they are derived from is found in Figure 4.1C. 
 
4.2.2 TAR iPSCs and HPCs Have Decreased RBM8A mRNA Expression  
To determine if the 1q21.1 deletion and SNPs result in a decrease in RBM8A/Y14 
expression, we differentiated TAR iPSCs into HPCs and MKs (Figure 4.2) and analyzed 
RBM8A/Y14 expression at various stages of the differentiation.  
 
All TAR iPSCs showed > 50% reduction in RBM8A expression as compared to WT 
iPSCs and this difference is maintained when they are differentiated towards mesoderm 
and HPCs (Figure 4.3A-C). CTL2 and CTL129 iPSCs, mesoderm and HPCs also 
showed decreased RBM8A expression similar to TAR lines (Figure 4.3A-C), suggesting 
that the bulk of this decrease in expression is due to the loss of one copy of the RBM8A 
gene in the deleted 1q21.1 region. Due to the difficulties in obtaining sufficient numbers 
of HPCs and MKs for western blotting, we only analyzed Y14 protein expression in TAR 
and control iPSCs (Figure 4.3D). Interestingly, only TAR1 iPSCs showed a significant 
decrease in Y14 expression as compared to WT iPSCs (Figure 4.3D), and even this 
decrease is smaller than expected based on RBM8A mRNA expression, suggesting that 
Y14 may be regulated differently at the protein and at the mRNA level. 
 
4.2.3 TAR iPSCs Showed Decreased MK Colony Formation and Abnormal 
Hematopoietic Potential  
To determine if TAR iPSCs showed defective hematopoiesis or megakaryopoiesis, we 
differentiated TAR iPSCs into HPCs, which can be further expanded in liquid culture to 
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MKs, or cultured in methocult or megacult assays to evaluate the hematopoietic colony 
forming potential, or MK colony-forming potential, respectively (Figure 4.2).  
 
TAR HPCs gave rise to fewer MK colonies than WT and CTL HPCs, suggestive of 
defective megakaryopoiesis (Figure 4.4A). However, megakaryopoiesis seemed 
relatively unaffected when we differentiated TAR HPCs in liquid culture (Figure 4.4B). 
Surprisingly, CTL2 HPCs also exhibited defective MK colony formation even though it is 
not derived from a patient (Figure 4.4A).  
 
In terms of hematopoietic potential, while TAR1 and TAR128 gave rise to fewer 
hematopoietic colonies across the board, TAR2 preferentially gave rise to erythroid 
colonies (Figure 4.4C). However, this preference to differentiate towards the erythroid 
lineage is not seen when we differentiated TAR2 HPCs in liquid culture (Figure 4.4B).  
 
The discrepancies in hematopoietic/megakaryocytic potential of TAR HPCs using 
different assays may be due to differences in the composition of megacult and methocult 
assays versus liquid culture. The nutrient-rich medium used in the liquid culture may 
provide extra stimulatory factors that can overcome some of the defects in 
megakaryopoiesis/hematopoiesis and mask the subtle phenotype.  
 
4.2.4 Restoring RBM8A Expression in TAR iPSCs Using a Doxycycline-inducible 
System Has Little or No Effect on Megakaryopoiesis  
Comparing the differentiation potential of TAR with WT iPSCs has its caveats: the 
genetic background of iPSCs affect their differentiation potential and this potential varies 
even amongst different WT iPSC lines. Thus, to better elucidate the TAR phenotype and 
the role in which RBM8A plays in hematopoiesis and megakaryopoiesis, we generated 
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isogenic corrected iPSC lines, where RBM8A expression is restored in TAR iPSC lines 
using a doxycycline-inducible system, which we will refer to as TAR TRE-RBM8A iPSCs. 
By comparing the differentiation of TAR TRE-RBM8A iPSCs with and without 
doxycycline addition, we can determine whether restoring RBM8A expression improves 
hematopoiesis or megakaryopoiesis and reveal subtle phenotypes, which are difficult to 
detect by comparing TAR iPSC lines with WT lines.  
 
To generate the TAR TRE-RBM8A iPSCs, we targeted two constructs into the AAVS1 
safe harbor locus. The first construct carries a constitutive promoter driving reverse 
tetracycline-controlled transactivator (RTTA) and the second construct carries a tet-
response element (TRE) driving RBM8A expression (Figure 2.1). In the presence of 
doxycycline, RTTA will bind to the TRE to drive RBM8A expression. The advantage of 
this system is that we can control the timing and level of RBM8A expression by the 
adding the appropriate concentration of doxycycline at the desired time.  
 
When doxycycline is added to TAR TRE-RBM8A iPSCs, we saw an increase in 
RBM8A/Y14 expression to a level that is comparable or greater than that in WT iPSCs 
(Figure 4.5A and B). However, when we compared the differentiation of TAR TRE-
RBM8A HPCs into MKs and erythrocytes in liquid culture with and without doxycycline, 
there were no significant changes in MK and erythrocyte numbers (Figure 4.5C). 
Similarly, there was no significant increase in MK colony formation when TAR TRE-
RBM8A HPCs were cultured in megacult with doxycycline (Figure 4.5D). These data 
suggest that increasing RBM8A expression in TAR HPCs does not affect hematopoiesis 
or megakaryopoiesis, thus it remains unclear whether decreased RBM8A expression is 
the cause of megakaryopoiesis defects in TAR syndrome.  
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4.2.5 Complete Deficiency of RBM8A is Lethal in iPSCs, HPCs, Erythrocytes and 
MKs 
To determine whether RBM8A plays a role in hematopoiesis/megakaryopoiesis, we 
examined whether a complete deficiency of RBM8A will block hematopoiesis or 
selectively affect megakaryopoiesis. Since RBM8A is part of the EJC, which is involved 
in essential cellular functions such as, enhancing the translation of spliced mRNAs and 
regulating nonsense mediated decay, it is highly likely that a complete deficiency of 
RBM8A will be lethal. Thus, we decided to knock out RBM8A in TAR TRE-RBM8A 
iPSCs in the presence of doxycycline, to maintain a basal level of RBM8A for survival 
during the gene knock out process, in case knocking out RBM8A is lethal. Additionally, 
since TAR TRE-RBM8A iPSCs only have 1 endogenous RBM8A allele (the other allele 
is deleted), it will be easier to knock out RBM8A in these cells. 
 
We generated the RBM8A knock out iPSCs using CRISPR/Cas9 technology and 
incorporated an oligo template for homology directed repair. The integration of the repair 
template into the RBM8A locus will lead to a premature stop codon 6 amino acids from 
the start site (Figure 2.2 and 4.6A) and thus, a truncated, non-functional RBM8A protein. 
We incorporated an XhoI restriction site into the repair template for screening purposes 
and mutated the PAM sequence to prevent re-cutting by the guide RNA (Figure 2.2 and 
4.6A).  
 
As expected, a complete deficiency of RBM8A is lethal to iPSCs. RBM8A knock-out 
iPSCs have to be cultured in the presence of doxycycline (minimum concentration: 0.03 
µg/ml) to maintain a basal level of RBM8A expression for survival. RBM8A expression in 
RBM8A knock-out iPSCs and hematopoietic cells correspond to the concentration of 
doxycycline present in the system (Figure 4.6B). Interestingly, even though we saw 
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significant decreases in mRNA expression as we titrate down the concentration of 
doxycycline, we did not observe a similar decrease at the protein level even when 
doxycycline concentration is titrated down to 0.05 µg/ml, suggesting that Y14 is highly 
regulated at the protein level (Figure 4.6C). However, when doxycycline is completely 
withdrawn from iPSCs for 16 and 48 hours, we see a rapid loss in Y14 protein (Figure 
4.6C), indicating that Y14 turns over quickly in cells. In these RBM8A knock-out iPSCs, 
Y14 expression is maintained by the continued presence of doxycycline driving constant 
transcription and translation of Y14.  
 
When RBM8A knock-out HPCs are differentiated to MKs and erythrocytes under various 
concentrations of doxycycline, viability of all cells decrease drastically with decreasing 
doxycycline concentrations (Figure 4.6D), suggesting that both MKs and erythrocytes 
are highly sensitive to reductions in RBM8A levels. Thus, a complete deficiency of 
RBM8A is lethal for all cell types, ranging from undifferentiated iPSCs to HPCs, MKs and 
erythrocytes. 
 
4.3 Discussion 
We used a pioneering approach to investigate the disease pathogenesis of TAR 
syndrome using patient-derived iPSCs from 3 different patients. We verified that all 3 
TAR iPSC lines carry a 1q21.1 deletion of varying lengths and a SNP in the non-coding 
region of the intact RBM8A allele. Based on the genotype of TAR patients, we predicted 
that TAR iPSCs and HPCs would have decreased RBM8A/Y14 expression. Although we 
found a consistent, significant reduction in RBM8A mRNA expression in TAR iPSCs and 
HPCs compared to their control/WT counterparts, it was unclear whether Y14 protein 
expression was lower in the TAR iPSCs. Albers et. al. showed decreased Y14 protein 
expression in platelet lysates obtained from TAR patients as compared to controls/WT.75 
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Thus, it is possible that Y14 protein expression may be regulated differently in 
undifferentiated cells versus differentiated hematopoietic cells, but due to technical 
difficulties in obtaining large numbers of pure MKs for western blotting, we were unable 
to determine whether Y14 protein expression is reduced in TAR MKs versus control/WT 
MKs.  
 
When we compared the hematopoietic and megakaryocytic potential of HPCs derived 
from TAR iPSCs and control/WT iPSCs, we observed a defect in MK colony forming 
ability, which was consistent with published literature.71–73 However, we did not find 
significant defects in MK differentiation when TAR HPCs were expanded in liquid culture, 
thus it remained unclear if there is a real defect in megakaryopoiesis in these cells. 
Since the genetic background of iPSCs has an important impact on its differentiation 
potential, we should ideally compare isogenic lines with the same genetic background. 
We reasoned that, if subthreshold RBM8A/Y14 expression were the underlying cause of 
the megakaryopoiesis defect in TAR syndrome, restoring RBM8A/Y14 expression would 
boost megakaryopoiesis in TAR HPCs and may also reveal subtle defects that we might 
have missed when comparing TAR HPCs to WT HPCs. Thus, we generated isogenic 
TAR TRE-RBM8A iPSC lines by restoring RBM8A expression in TAR iPSC lines by 
targeting a doxycycline-inducible transgene expression system into the AAVS1 safe 
harbor locus.  We were able to restore RBM8A expression during hematopoiesis and 
megakaryopoiesis by adding doxycycline to TAR TRE-RBM8A iPSCs, but we did not 
observe any significant improvement in MK differentiation or MK colony forming ability. 
These results suggest that basal RBM8A/Y14 expression in TAR TRE-RBM8A iPSCs 
may be sufficient for megakaryopoiesis and that any further increase in expression does 
not further improve megakaryopoiesis. 
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To determine if RBM8A plays any role in hematopoiesis or megakaryopoiesis, we 
decided to take a step further and knock out RBM8A completely. Unsurprisingly, a 
complete deficiency of RBM8A is lethal to iPSCs, HPCs and differentiated hematopoietic 
cells. We titrated different concentrations of doxycycline to vary RBM8A expression 
levels to determine if MKs are more sensitive to RBM8A levels than other hematopoietic 
cells, e.g., erythrocytes. We found that the viability of MKs and erythrocytes decrease 
drastically with decreasing levels of doxycycline/RBM8A expression and that MKs and 
erythrocytes are both equally sensitive to RBM8A levels.  
 
In conclusion, we were not able elucidate the role of RBM8A in TAR syndrome or fully 
recapitulate the TAR syndrome phenotype using patient-derived iPSCs. An interesting 
feature of TAR syndrome is that platelet counts in patients usually recover to near 
normal levels over time, suggesting that the defect in megakaryopoiesis/ thrombopoiesis 
is perhaps specific to fetal/neonatal stage of life. The differentiation of iPSCs into the 
various hematopoietic lineages in vitro recapitulates yolk sac primitive hematopoiesis, 
which occurs during the embryonic phase of life. It is possible that the MKs during the 
embryonic stage of development are less sensitive to RBM8A levels or that RBM8A 
expression is regulated differently at that stage. Differentiation protocols to direct iPSCs 
towards definitive/fetal hematopoietic progenitors and MKs may be necessary to 
elucidate the TAR syndrome phenotype. Alternatively, additional genes affected by the 
deletion in TAR syndrome may also contribute to the observed phenotype in patients.  
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Figure 4.1 
 
 
 
 
Figure 4.1: TAR iPSC Lines Carry a Deletion in the Chromosome Region 1q21.1 
and a SNP in the 5’ UTR or 3’ UTR of the Intact RBM8A Allele (A) Copy number 
variance analysis comparing TAR and control (CTL) iPSC lines. Deletion (blue) and 
amplification (red) of regions in chromosome region 1q21.1 are shown. (B) Partial 
sequences of TAR and control iPSC lines in the 5’ UTR (left) and 3’ UTR (right) of 
RBM8A gene. The disease-associated SNPs are highlighted in red. The STOP codon is 
highlighted in blue. (C) Summary of the genotypes of iPSC lines and who they are 
derived from. 
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Figure 4.2 
 
Figure 4.2: Differentiation Schematic for iPSCs (A) Representative flow cytometric 
profiles for iPSCs (SSEA3+ SSEA4+), mesoderm (KDR+, CD31+) and HPCs (CD41+, 
CD235a+) on days 0, 5 and 8 of hematopoietic differentiation. D8 HPCs can be 
expanded in liquid culture (B) or further differentiated in methocult (C) or megacult (D) 
assays for evaluation of hematopoietic or megakaryocytic potential respectively. (B) 
Representative flow cytometric profiles for CD41-CD235a+ erythrocytes and CD41+ 
CD42+ MKs after 5 days of differentiation. (C) Representative images of hematopoietic 
colonies after 12 days of culture in methocult: Colony forming unit-granulocyte, 
erythrocyte, monocyte, megakaryocyte (CFU-GEMM), Colony forming unit-granulocyte, 
monocyte (CFU-GM), Colony forming unit-erythrocyte (CFU-E). (D) Representative 
image of MK colony post-fixation and staining after 12 days of culture in megacult. 
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Figure 4.3  
 
Figure 4.3: RBM8A mRNA and Y14 Protein Expression in TAR, CTL and WT iPSCs 
and Differentiated Cells RBM8A mRNA expression in (A) TAR and control iPSCs (n ≥ 
2), (B) mesoderm derived from TAR and control iPSCs.(n ≥ 2), (C) HPCs derived from 
TAR and control iPSCs. (n ≥ 2). (D) (Top) Representative western blot showing Y14 and 
beta actin protein expression in TAR and control iPSCs. (Bottom) Quantification of Y14 
protein expression in TAR and control iPSCs (n ≥ 2) *p < 0.05, **p < 0.01, ***p<0.001, 
****p<0.0001 comparing RBM8A/Y14 expression in WT versus TAR as indicated.  
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Figure 4.4 
 
Figure 4.4: Hematopoietic Phenotype of TAR iPSCs (A) Day 8 HPCs were plated in 
MegacultTM collagen-based medium for MK colony formation. Number of MK colonies 
were enumerated after 12 days in culture. *p < 0.05 comparing TAR1 versus WT and 
**p<0.01 comparing TAR2 versus WT. (n ≥ 2). (B) Day 8 HPCs were differentiated into 
erythrocytes and MKs in liquid culture. Bar graph shows the quantification of the number 
of erythrocytes and MKs after 5 days in culture. (n ≥ 4). Differences between TAR versus 
WT were not significant. (C) Day 8 HPCs were plated in MethocultTM methylcellulose 
medium for hematopoietic colony formation. Number and types of colonies were 
enumerated after 12 days in culture. CFU-GEMM: colony forming unit-granulocyte, 
erythrocyte, monocyte, megakaryocyte; CFU-GM: colony forming unit-granulocyte, 
monocyte; CFU-E: colony forming unit-erythrocyte. (n ≥ 2). 
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Figure 4.5 
 
Figure 4.5: Restoring RBM8A Expression in TAR iPSCs Using a Doxycycline-
inducible Transgene Expression System (A) RBM8A mRNA expression in TAR iPSC 
lines with doxycycline (dox)-inducible RBM8A expression (TAR1 TRE-RBM8A and TAR2 
TRE-RBM8A) in the absence (black) or presence (pink) of 2 µg/ml of dox. **p < 0.01 and 
***p<0.001 comparing RBM8A expression with and without the addition of dox. (n ≥ 9) 
(B) Representative western blot showing Y14 and beta actin protein expression in TAR1 
and TAR1 TRE-RBM8A iPSCs in the presence and absence of dox. (C) Day 8 HPCs 
were differentiated into MKs and erythrocytes for 5 days in liquid culture. Bar graph 
shows the quantification of the number of MKs and erythrocytes in the absence (black) 
and presence (pink) of 2 µg/ml of dox. Differences between conditions with and without 
dox were not significant. (n ≥ 3) (D) Day 8 HPCs were plated in MegacultTM assay in the 
absence (black) or presence (pink) of 2 µg/ml of dox for MK colony formation. Bar graph 
quantification of the number of MK colonies after 12 days is shown. The differences 
between conditions with and without dox were not significant. (n = 2) 
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Figure 4.6 
 
Figure 4.6: A Complete Deficiency of RBM8A is Lethal to Both iPSCs and 
Hematopoietic Cells (A) The CRISPR/Cas9 system was used to knock out RBM8A in 
TAR2-TRE-RBM8A iPSCs. The genomic sequence of RBM8A aligned with the edited 
sequence is shown. The ATG start site is marked in green. The PAM sequence (orange) 
is mutated to prevent recutting by Cas9. A STOP codon (red) is created by the insertion 
of a single base T. An XhoI restriction site (blue) is created for screening by a single 
base substitution from A to T. (B) RBM8A mRNA expression in RBM8A-knockout 
(RBM8A-KO) iPSCs and hematopoietic cells derived from these iPSCs at various 
doxycycline (dox) concentrations. (n = 3) (C) (Top) Representative western blot showing 
Y14 and beta actin protein expression of RBM8A knockout iPSCs cultured under 
decreasing dox concentrations and when dox was removed for 16 and 48 hours. 
(Bottom) Bar graph quantifying Y14 protein expression of RBM8A knockout iPSCs under 
these conditions. ***p < 0.001 comparing Y14 protein expression in the presence of 1 
µg/ml of dox and when dox was removed for 16 and 48 hours. p value was determined 
by the student’s t test. (D) RBM8A-KO iPSCs were differentiated into HPCs with 2 µg/ml 
of dox. Day 8 HPCs were differentiated into MKs and erythrocytes in liquid culture at 
various dox concentrations. Graph quantifying the total number of live cells (black 
triangles), MKs (blue squares) and erythrocytes (red circles) after 5 days in culture is 
shown. (n = 3) 
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CHAPTER 5 
Conclusions and Future Directions 
 
In conclusion, we have used human stem cell-derived MKs to address two important 
questions in the field of megakaryopoiesis and thrombopoiesis: 1) to define the features 
of a mature MK optimally primed to release platelets, 2) to understand the disease 
mechanism of TAR syndrome. We showed that the ability to take up FV is a defining 
feature of mature MKs that are ready to release platelets and that this transient mature 
population can be enriched by protecting them from apoptosis. Next, we recapitulated a 
partial phenotype of TAR syndrome using patient-specific iPSCs but did not find a 
specific role for RBM8A in primitive (embryonic) hematopoiesis or megakaryopoiesis. 
These results form the basis for future work, which will help refine our understanding of 
megakaryopoiesis and thrombopoiesis, and in turn, improve the efficiency of generating 
stem cell-derived platelets for transfusions.  
 
5.1 Using FV-labeled MKs as a Tool to Uncover New Maturation Markers and 
Mechanisms 
Traditionally, mature MKs are defined by high surface CD42b expression,33 increased 
expression of maturation genes (e.g. NFE2, TUBB1, PF4),34 high ploidy,35 high alpha-
granule and RNA content.37,39–41 We can now go one step further and define mature 
platelet-ready MKs as those that can take up FV efficiently, as this ability is acquired 
after peak expression of the known maturation markers mentioned above.  
 
Purifying the mature MKs from the heterogeneous, asynchronous culture is important for 
several reasons: 1) we can improve the efficiency of platelet production by infusing only 
the mature platelet-ready MKs into a platelet bioreactor or potentially a person, and 
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allowing the immature MKs more time to develop; 2) we can purify the mature MKs for 
gene expression analysis and further functional analysis to improve the characteristics of 
this specific population.  Although mature MKs can be purified from bulk culture by 
sorting for MKs that have internalized FV, the stress of cell sorting may compromise its 
functionality in downstream assays, for instance platelet release in a platelet bioreactor.  
A better strategy would be to isolate them based on cell surface receptors, which will 
allow gentler methods of purification like magnetic bead sorting. Thus, moving forward, 
transcriptome studies to compare CD42bhigh/FV- and CD42bhigh/FV+ MKs may be useful 
for identifying novel surface markers on CD42bhigh/FV+ MKs that are not present on 
CD42bhigh/FV- MKs. Moreover, such studies may also reveal additional late markers of 
MK maturation, beyond what we already know.  
 
Potential cell surface markers for isolating mature MKs would include receptors involved 
in FV internalization as their expression levels are likely to increase as MKs acquire the 
ability to endocytose FV. We found that LRP1 surface expression is upregulated on 
mature HG/CD42b+ MKs as compared to immature LG MKs, which correlates well with 
the idea that LRP1 is the putative receptor for FV endocytosis.156 However, LRP1 
surface expression is too low to be a useful surface marker for purifying mature MKs. If 
we can generate a reporter line, which expresses enhanced green fluorescent protein 
under the LRP1 promoter, this could potentially improve the LRP1 signal and the ease of 
isolating LRP1high MKs.  
 
Another potential marker is galectin-8, which has recently been identified as a 
glycoprotein expressed on MKs that interacts specifically and directly with FV.180 
Additionally, blockage of this glycoprotein by antibodies impair FV endocytosis, 
suggesting that it plays an important role in FV endocytosis, perhaps by binding FV and 
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transferring it to LRP1 for endocytosis.156,180 Examining the surface expression of 
galectin-8 in mature and immature MKs and correlating its expression levels with the 
ability to internalize FV would be the first step to determine if galectin-8 could be a 
suitable cell surface receptor for isolating mature MKs that are capable of taking up FV. 
 
We have demonstrated that FV+ MKs releases functional FV+ platelets in vivo when 
infused and gives rise to partially functional FV+ platelet-like particles in vitro. Going 
further, it would be interesting to infuse FV-labeled MKs into a platelet bioreactor to see 
if FV+ MKs preferentially release functional platelets as compared FV- MKs. Several 
versions of platelet bioreactors have been developed over the years, which are known to 
give higher platelet yields as compared to static MK cultures.102,103,106,137 These 
bioreactors incorporate elements to mimic the bone marrow microenvironment including 
endothelial cell contacts, extracellular matrix components and shear stress to stimulate 
and enhance platelet production.102,103,106,137 Examining platelet release from FV-labeled 
MKs using these improved systems may give additional insights, in particular, it will be 
interesting to see if these systems generate FV+ platelets of higher quality and 
functionality. 
 
To examine platelet formation from FV-labeled MKs in its natural, physiological 
environment, we can use techniques like two photon intravital microscopy to directly 
visualize proplatelet formation in the bone marrow sinusoids or in the lung following the 
infusion of FV-labeled MKs into immunodeficient mice. The hypothesis is that FV+ MKs 
will release platelets quickly in the lung or bone marrow sinusoids post-infusion while FV- 
MKs may linger and release platelets much later. Assessing the functionality of FV-
labeled MKs in platelet bioreactors, in the bone marrow sinusoids and in the lung will 
give further validation to our idea that FV uptake defines mature platelet-ready MKs. 
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Demonstrating that we can detect fluorescently-labeled FV in the alpha-granules of 
human stem cell-derived MKs established a unique human model system for studying 
the mechanism of protein endocytosis by human MKs, which is critical since the murine 
model is not optimum for these studies as mouse MKs produce FV endogenously.   
Since human MKs are known to endocytose other proteins such as immunoglobulins or 
fibrinogen,43,51,52,173 we can potentially label these proteins with fluorescent probes and 
analyze whether uptake of these molecules occur at the same stage of maturation and 
whether they are sorted into the same or different compartments.  
 
Mechanistic studies on the uptake, trafficking and packaging of FV and other proteins 
within MKs and how they are eventually distributed into platelets may provide new 
insights into alpha-granule biology in MK and platelets. For instance, incubation of MKs 
with different variants of FV may reveal specific FV regions or amino acid residues that 
are crucial for the binding interaction and subsequent endocytosis. Knocking out or 
mutations of LRP-1 and/or galectin-8 in human stem cell-derived MKs by CRISPR/Cas9 
system will further crystallize the involvement of these receptors in the endocytosis of 
FV. A detailed time course looking at the colocalization of FV with various known 
proteins important for alpha-granule biogenesis at different time points following 
incubation of FV with MKs may give additional insights to the specific trafficking route of 
FV through the cell following endocytosis.  
 
In human plasma, FV concentrations range from 12 – 42 nM, with a mean concentration 
of 20 nM. In our initial optimization studies, we titrated FV concentrations ranging from 
20 nM to 200 nM over a period of 1 hour to 24 hours and found that FV uptake increases 
with the external concentration of FV and the amount of time MKs were exposed to FV, 
suggesting that FV uptake by MKs may be regulated simply by its exposure to FV in the 
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natural environment. This means that to make truly functional platelets with the right 
amount of FV, we need to more carefully quantify the kinetics of FV uptake by MKs, the 
amount of FV taken up by MKs under various incubation conditions and the amount of 
FV required in platelets for normal function. Similar assays are also needed for other 
proteins that are endocytosed by MKs like fibrinogen and immunoglobulins. 
 
5.2 Exploring the Role of Apoptosis in Platelet Formation In Vitro and In Vivo 
Using Human Stem Cell Models 
The question of whether apoptosis plays a role in platelet formation remains 
controversial as there are evidences for both sides of the story. Initial studies supporting 
the role of apoptosis in platelet formation demonstrated that treatment of human stem 
cell-derived MKs with pharmacological inhibitors of apoptosis led to decreased 
proplatelet formation in vitro175,176 and that Fas ligand-induced extrinsic apoptosis in MK 
cell lines or primary murine MKs increases the yield of PLPs in vitro.176  
 
However, studies from mice with MK-specific or hematopoietic-specific deletions of the 
key mediators of intrinsic apoptosis Bax and Bak or caspase 9 showed that the inability 
to activate intrinsic apoptosis did not affect platelet counts.177,179  Furthermore, mice 
deficient in pro-survival protein B cell lymphoma-extra large (BCL-XL) displayed 
increased MK apoptosis and failed to shed platelets, suggesting that restraining 
apoptosis is necessary to help MKs survive and shed platelets.179 More recently, a triple 
knockout mouse with deficiencies in proteins essential for both intrinsic (Bax and Bak) 
and extrinsic apoptosis (caspase 8) showed normal platelet production, lending further 
support to the idea that apoptosis is dispensable for platelet formation at least in mice, in 
vivo.178  
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In humans, BH3 mimetics, a class of cancer drugs that induce apoptosis in cells through 
its inhibition on pro-survival proteins such as BCL-XL, led to thrombocytopenia at high 
doses181–183, suggesting that apoptosis may be detrimental to platelet production and 
survival. A mutation of human cytochrome c that enhances intrinsic apoptosis led to 
premature release of platelets into the marrow space instead of the sinusoids, resulting 
in thrombocytopenia.166 When CD34+ HPCs isolated from patients carrying the mutated 
cytochrome c were differentiated into MKs and platelets, there was early and enhanced 
production of CD41+ PLPs,166 suggesting that PLPs arise through an apoptotic process 
in vitro. Collectively, the contradictory conclusions from these different studies could be 
due to differences between in vivo and in vitro systems.  
 
We showed that mature MKs in culture are being damaged by apoptosis and by keeping 
them viable until they are infused into the right environment in vivo increases platelet 
yield. However, mature MKs cultured in the presence of apoptosis inhibitor resulted in 
decreased PLP production in vitro. Based on these results, we may hypothesize that 
platelet formation in vitro and in vivo may be different and that in vitro PLPs may be 
products of apoptosis. We can begin to test this hypothesis by knocking out components 
of the intrinsic and extrinsic apoptotic pathway (Bak, Bax, caspase 9 and 8) singly and in 
combination in human stem cell-derived MKs using the CRISPR/Cas9 system and 
examining the effects of these manipulations on MK viability and platelet formation in 
vitro and in vivo. These experiments are complementary to previously published work 
and will shed light on whether there is a difference between in vitro and in vivo platelet 
formation.  
 
In our studies, Q-VD-Oph, a pan-caspase inhibitor,161,162 was able to restrain apoptosis 
but could not eliminate it completely. With Q-VD-Oph, MKs were able to maintain their 
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viability for a longer time but would eventually succumb to apoptosis if they were 
cultured for an extended period of time. Additionally, the effect this drug is temporary as 
its removal led to a quick progression of cells towards apoptosis. The limitation of Q-VD-
Oph may be due to the fact that it interferes at the level of caspases, which occurs after 
mitochondrial outer membrane permeabilization (MOMP), often recognized as the “point 
of no return” in the intrinsic apoptotic cascade.184 Inhibiting apoptosis before MOMP 
occurs could be a good way to more permanently or effectively protect the viability of 
MKs. We tried to inhibit apoptosis using cyclosporine A, Bax inhibiting peptide V5 and 
mitochondrial division inhibitor-1 (mdivi-1), which block apoptosis at the level of 
MOMP,185–187 but surprisingly, these inhibitors were not successful at inhibiting apoptosis 
at the range of doses that we tested. We and others have found that MKs in culture are 
not able to reach the size and ploidy of MKs in their natural in vivo environment,25,136 
which may be the limiting factor for platelet yield. We start to see apoptosis in our MK 
cultures from day 13 and without any intervention, apoptotic MKs quickly take over the 
culture. We may hypothesize that MKs in culture are not able to achieve high ploidy 
because they become apoptotic. Although Q-VD-Oph protected the MKs from apoptosis, 
we did not see an improvement in ploidy, probably due to its late intervention. Future 
efforts to protect MK viability by preventing MOMP and examining the effect of apoptosis 
protection on MK ploidy could employ the use of human stem cell-derived MKs 
genetically modified to knock out proteins necessary for MOMP (e.g. cyclophilin D, Bax 
and Bak).  
 
5.3 In Vitro Platelet Generation Versus MK Infusion? 
There are two potential ways of increasing platelet count in thrombocytopenic patients 
using stem cell-derived products. We can either infuse stem cell-derived platelets that 
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are generated in vitro or infuse stem cell-derived MKs that can give rise to platelets in 
the circulation.  
 
The advantages of infusing in vitro-generated platelets over MKs directly include: 1) 
better control of the number of platelets that are infused; 2) the platelet product can be 
irradiated to remove any other contaminating cell types, especially undifferentiated stem 
cells, which have teratoma-forming potential. However, it is extremely challenging to 
produce real, functional platelets in vitro because the microenvironment and the signals 
controlling platelet release are complicated and cannot be easily mimicked even with 
much improved in vitro systems, like platelet bioreactors. Our studies and others showed 
that the yield and purity of functional CD42b+ PLPs from a static MK culture is very 
low.88,89 Moreover, even the CD42b+ PLPs have limited functionality compared to donor 
platelets as indicated by a smaller fold change of surface P-selectin, a marker of 
activation and degranulation in platelets. Presently, the in vitro-generated platelets also 
lack FV, fibrinogen and immunoglobulins, proteins that are crucial for their function. 
These proteins, normally endocytosed by MKs in their natural environment and 
transferred to platelets, are not present in the culture medium. Incubation of MKs with 
these factors prior to platelet production should be an essential step in the protocol of 
generating functional in vitro platelets.  
 
In contrast, the advantages of infusing MKs over in vitro-generated platelets include: 1) 
the potential for sustained release of platelets over an extended period of time, which 
reduces the need for frequent transfusions, 2) the possibility of building up frozen stocks 
of expandable MKs for emergency use, and 3) the ability to take advantage of the 
natural in vivo microenvironment for efficient platelet production.  
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The greatest concern over infusing MKs as a therapeutic strategy is the potential danger 
of infused MKs blocking pulmonary capillaries during platelet release. Preliminary 
studies suggest that infusions of up to 5.45 x 106 MK progenitors are safe and tolerable 
but these treatments did not show substantial evidence of efficacy.116–118 Perhaps the 
number of MK progenitors infused need to be further optimized or perhaps mature 
platelet-ready MKs instead of MK progenitors should be infused to improve efficacy. 
Recent advances strengthen the model that MKs travel to the lung capillary bed to 
release platelets into the circulation by providing evidence that thrombopoiesis in the 
lung accounts for 50% of the total platelet output.69 If thrombopoiesis naturally occurs in 
the lung, there should be an excess of pulmonary capillaries such that the small 
percentage of capillaries blocked by MKs during platelet release at any time,188 should 
not significantly affect blood flow. Extensive research would be needed to determine the 
optimum number of mature MKs to infuse to maximize safety and efficacy.  
 
Additionally, ascertaining the functionality of platelets produced in vivo from infused MKs 
is also a challenge due to the low yield of platelets and the difficulty of isolating the 
platelets derived from infused MKs from endogenous platelets for functionality assays. 
We have demonstrated that platelets derived from infused MKs in immunodeficient mice 
activate in response to agonists and incorporate into clots following laser injury,113 which 
are good preliminary indicators of functionality. However, the laser injury model is 
imperfect for assessing human platelet functionality as human platelets interact poorly 
with mouse VWF, thus human platelet incorporation rates into the mouse’s thrombus are 
very low regardless of their functionality. We can improve this model by engineering a 
mouse model that expresses VWF with enhanced specificity for human platelets.114 To 
investigate platelet functionality more extensively, we can also use thrombocytopenic 
mouse models to see if infused MKs can cause an appreciable increase in platelet 
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counts to reverse thrombocytopenia. Lastly, platelet yields have to be massively 
improved before we can even begin to analyze their functionality using assays like LTA, 
which is the gold standard assessment for platelet functionality. 
 
5.4 Directing iPSCs to Definitive (Adult) HPCs and MKs Could Be Informative for 
Elucidating the Mechanism of TAR Syndrome 
We were unable to fully recapitulate the hematologic features of TAR syndrome by 
differentiating TAR patient-specific iPSCs into HPCs and MKs, perhaps because these 
HPCs and MKs are primitive (embryonic) in nature and the developmental defects are 
only present in the definitive (adult) lineages. No one has successfully generated adult 
hematopoietic stem cells from iPSCs/ESCs, but advances have been made in protocols 
to generate early definitive-like hematopoietic progenitors that have broader 
hematopoietic potentials.189–191 Using these improved protocols to differentiate TAR 
patient-specific iPSCs into more definitive-like hematopoietic progenitors may reveal 
hematologic phenotypes that are more similar to that observed in patients. 
Recapitulating the patient’s phenotype using patient-specific iPSCs will be the first step 
towards elucidating the disease mechanism and revealing the elusive role of RBM8A in 
megakaryopoiesis and thrombopoiesis. If we can recapitulate the TAR syndrome 
phenotype starting from more definitive-like hematopoietic progenitors but not from 
primitive progenitors, this will be an interesting starting point for investigating the 
differences between primitive (embryonic) MKs and definitive (adult) MKs, an area that is 
not yet well-understood.  
 
Primitive (embryonic) MKs are more proliferative but have lower ploidy as compared to 
definitive (adult) MKs. Transcriptome analyses comparing human ESC-derived MKs with 
primitive yolk sac-derived MKs and definitive fetal liver and definitive adult CD34+ HPCs 
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derived MKs showed that ESC-derived MKs are most similar to primitive yolk-sac-
derived MKs,24 which is unsurprising since we know that in vitro differentiation of ESCs 
and iPSCs to HPCs recapitulates primitive hematopoiesis.28,29 Additionally, more than 
1/3 of the genes that were continuously upregulated with MK ontogeny were 
cytoskeleton proteins and proteins involved in polyploidization, proplatelet formation and 
platelet functions, an potential explanation for why definitive adult MKs may be better 
platelet producers than primitive embryonic MKs.24 Future work to understand the 
differences in the regulation of primitive and definitive megakaryopoiesis and to 
recapitulate definitive megakaryopoiesis from ESCs and iPSCs will have important 
implications for the generation of stem cell-derived platelets and the use of iPSCs for 
modeling diseases with defects in MK development, maturation and platelet production. 
Figuring out whether platelets released by primitive MKs function similarly as adult 
human donor platelets is crucial to determine whether the platelets we get from 
iPSCs/ESCs will ever be good enough for transfusion without undergoing definitive 
megakaryopoiesis through a HSC intermediate. Lastly, understanding whether a 
MK/platelet developmental defect is primitive or definitive in origin will be important to 
determine what differentiation protocols are needed to recapitulate the phenotype and 
elucidate the disease mechanism.  
 
 
 
 
 
 
 
 
	  	  	   97 
Bibliography 
1. Pease D. An Electron Microscopic Study of Red Bone Marrow. Blood. 
1956;11(6):501–526.  
2. Nakeff A, Maat B. Separation of Megakaryocytes From Mouse Bone Marrow by 
Velocity Sedimentation. Blood. 1974;43(4):591–595.  
3. Bruns I, Lucas D, Pinho S, et al. Megakaryocytes regulate hematopoietic stem cell 
quiescence via CXCL4 secretion. Nat. Med. 2014;20(11):1315–1320.  
4. Zhao M, Perry JM, Marshall H, et al. Megakaryocytes maintain homeostatic 
quiescence and promote post-injury regeneration of hematopoietic stem cells. 
Nat. Med. 2014;20(11):1321–1326.  
5. Golebiewska EM, Poole AW. Platelet secretion: From haemostasis to wound 
healing and beyond. Blood Rev. 2015;29(3):153–162.  
6. Nurden AT, Nurden P, Sanchez M, Andia I, Eduardo A. Platelets and wound 
healing. Front. Biosci. 2008;13(i):3532–3548.  
7. Walsh TG, Metharom P, Berndt MC. The functional role of platelets in the 
regulation of angiogenesis. Platelets. 2014;7104(3):1–13.  
8. Ware J, Corken A, Khetpal R. Platelet function beyond hemostasis and 
thrombosis. Curr. Opin. Hematol. 2013;20(5):451–456.  
9. Jenne CN, Kubes P. Platelets in inflammation and infection. Platelets. 
2015;26(4):286–292.  
10. Bertozzi CC, Hess PR, Kahn ML. Platelets: Covert regulators of lymphatic 
development. Arterioscler. Thromb. Vasc. Biol. 2010;30(12):2368–2371.  
11. Akashi K, Traver D, Miyamoto T, Weissman IL. A clonogenic common myeloid 
progenitor that gives rise to all myeloid lineages. Nature. 2000;404:193–197.  
12. Manz MG, Miyamoto T, Akashi K, Weissman IL. Prospective isolation of human 
clonogenic common myeloid progenitors. Proc. Natl. Acad. Sci. U. S. A. 
2002;99(18):11872–11877.  
13. Debili N, Coulombel L, Croisille L, et al. Characterization of a bipotent erythro-
megakaryocytic progenitor in human bone marrow. Blood. 1996;88(4):1284–1296.  
14. Woolthuis CM, Park CY. Hematopoietic stem/progenitor cell commitment to the 
megakaryocyte lineage. Blood. 2016;127(10):1242–1248.  
15. Sanjuan-Pla A, Macaulay IC, Jensen CT, et al. Platelet-biased stem cells reside at 
the apex of the haematopoietic stem-cell hierarchy. Nature. 2013;502(7470):232–
6.  
16. Shin JY, Hu W, Naramura M, Park CY. High c-Kit expression identifies 
hematopoietic stem cells with impaired self-renewal and megakaryocytic bias. J. 
Exp. Med. 2014;211(2):217–231.  
17. Yamamoto R, Morita Y, Ooehara J, et al. Clonal analysis unveils self-renewing 
lineage-restricted progenitors generated directly from hematopoietic stem cells. 
Cell. 2013;154(5):1112–1126.  
18. Nishikii H, Kanazawa Y, Umemoto T, et al. Unipotent megakaryopoietic pathway 
bridging hematopoietic stem cells and mature megakaryocytes. Stem Cells. 
2015;33(7):2196–2207.  
19. Tavian M, Péault B. Embryonic development of the human hematopoietic system. 
Int. J. Dev. Biol. 2005;49(2–3):243–250.  
20. McGrath KE, Palis J. Hematopoiesis in the yolk sac: More than meets the eye. 
Exp. Hematol. 2005;33(9 SPEC. ISS.):1021–1028.  
21. Palis J, Robertson S, Kennedy M, Wall C, Keller G. Development of erythroid and 
myeloid progenitors in the yolk sac and embryo proper of the mouse. 
Development. 1999;126(22):5073–5084.  
	  	  	   98 
22. Xu M J, Matsuoka S, Yang FC, et al. Evidence for the presence of murine 
primitive megakaryocytopoiesis in the early yolk sac. Blood. 2001;97(7):2016–
2022.  
23. Tober J, McGrath KE, Palis J. Primitive erythropoiesis and megakaryopoiesis in 
the yolk sac are independent of c-myb. Blood. 2008;111(5):2636–2639.  
24. Bluteau O, Langlois T, Rivera-Munoz P, et al. Developmental changes in human 
megakaryopoiesis. J. Thromb. Haemost. 2013;11(9):1730–41.  
25. Mattia G, Vulcano F, Milazzo L, et al. Different ploidy levels of megakaryocytes 
generated from peripheral or cord blood CD34+ cells are correlated with different 
levels of platelet release. Blood. 2002;99(3):888–897.  
26. Potts KS, Sargeant TJ, Markham JF, et al. A lineage of diploid platelet-forming 
cells precedes polyploid megakaryocyte formation in the mouse embryo. Blood. 
2014;124(17):2725–2730.  
27. Tober J, Koniski A, McGrath KE, et al. The megakaryocyte lineage originates from 
hemangioblast precursors and is an integral component both of primitive and of 
definitive hematopoiesis. Blood. 2007;109(4):1433–1441.  
28. Murry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant 
populations: lessons from embryonic development. Cell. 2008;132(4):661–680.  
29. Klimchenko O, Mori M, DiStefano A, et al. A common bipotent progenitor 
generates the erythroid and megakaryocyte lineages in embryonic stem cell-
derived primitive hematopoiesis. Blood. 2009;114(8):1506–1517.  
30. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a 
physiological regulator of megakaryocyte growth and platelet production. Proc. 
Natl. Acad. Sci. U. S. A. 1994;91:11104–11108.  
31. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine 
thrombopoietin cDNA and stimulation of platelet production in vivo. Nature. 
1994;369:565–568.  
32. Kaushansky K, Broudy VC, Lin N, et al. Thrombopoietin, the Mp1 ligand, is 
essential for full megakaryocyte development. Proc. Natl. Acad. Sci. U. S. A. 
1995;92(8):3234–3238.  
33. Debili N, Issaad C, Massé JM, et al. Expression of CD34 and platelet 
glycoproteins during human megakaryocytic differentiation. Blood. 
1992;80(12):3022–3035.  
34. Tijssen MR, Ghevaert C. Transcription factors in late megakaryopoiesis and 
related platelet disorders. J. Thromb. Haemost. 2013;11(4):593–604.  
35. Vitrat N, Cohen-Solal K, Pique C, et al. Endomitosis of human megakaryocytes 
are due to abortive mitosis. Blood. 1998;91(10):3711–3723.  
36. Radley J, Haller C. The demarcation membrane system of the megakaryocyte: A 
misnomer? Blood. 1982;60(1):213–219.  
37. Heijnen HF, Debili N, Vainchencker W, et al. Multivesicular bodies are an 
intermediate stage in the formation of platelet alpha-granules. Blood. 
1998;91(7):2313–2325.  
38. Youssefian T, Cramer EM. Megakaryocyte dense granule components are sorted 
in multivesicular bodies. Blood. 2000;95(12):4004–4007.  
39. Fava RA, Casey TT, Wilcox J, et al. Synthesis of transforming growth factor-beta 
1 by megakaryocytes and its localization to megakaryocyte and platelet alpha-
granules. Blood. 1990;76(10):1946–1955.  
40. Schick PK, Walker J, Profeta B, Denisova L, Bennett V. Synthesis and secretion 
of von willebrand factor and fibronectin in megakaryocytes at different stages of 
maturation. Arterioscler. Thromb. Vasc. Biol. 1997;17:797–801.  
41. Lambert MP, Meng R, Xiao L, et al. Intramedullary megakaryocytes internalize 
	  	  	   99 
released platelet factor 4 and store it in alpha granules. J. Thromb. Haemost. 
2015;13(10):1888–1899.  
42. Suehiro Y, Veljkovic DK, Fuller N, et al. Endocytosis and storage of plasma factor 
V by human megakaryocytes. Thromb. Haemost. 2005;94:585–592.  
43. Harrison P, Wilbourn B, Debili N, et al. Uptake of plasma fibrinogen into the alpha 
granules of human megakaryocytes and platelets. J. Clin. Invest. 
1989;84(4):1320–1324.  
44. Handagama PJ, George JN, Shuman MA, McEver RP, Bainton DF. Incorporation 
of a circulating protein into megakaryocyte and platelet granules. Proc. Natl. Acad. 
Sci. U. S. A. 1987;84(3):861–865.  
45. Raslova H, Roy L, Vourc’h C, et al. Megakaryocyte polyploidization is associated 
with a functional gene amplification. Blood. 2003;101(2):541–544.  
46. Raslova H, Kauffmann A, Sekkaï D, et al. Interrelation between polyploidization 
and megakaryocyte differentiation: a gene profiling approach. Blood. 
2007;109(8):3225–34.  
47. Schulze H, Korpal M, Hurov J, et al. Characterization of the megakaryocyte 
demarcation membrane system and its role in thrombopoiesis. Blood. 
2006;107(10):3868–3875.  
48. Antkowiak A, Viaud J, Severin S, et al. Cdc42-dependent F-actin dynamics drive 
structuration of the demarcation membrane system in megakaryocytes. J. 
Thromb. Haemost. 2016;14(6):1268–1284.  
49. Rowley JW, Schwertz H, Weyrich AS. Platelet mRNA: the meaning behind the 
message. Curr. Opin. Hematol. 2012;19(5):385–391.  
50. Roth GJ, Hickey MJ, Chung DW, Hickstein DD. Circulating human blood platelets 
retain appreciable amounts of poly (A)+ RNA. Biochem. Biophys. Res. Commun. 
1989;160(2):705–710.  
51. Handagama P, Rappolee DA, Werb Z, Levin J, Bainton DF. Platelet α-Granule 
fibrinogen, albumin, and immunoglobulin G are not synthesized by rat and mouse 
megakaryocytes. J. Clin. Invest. 1990;86:1364–1368.  
52. Handagama P, Scarborough RM, Shuman MA, Bainton DF. Endocytosis of 
fibrinogen into megakaryocyte and platelet alpha-granules is mediated by alpha 
IIb beta 3 (glycoprotein IIb-IIIa). Blood. 1993;82:135–138.  
53. Klement GL, Yip TT, Cassiola F, et al. Platelets actively sequester angiogenesis 
regulators. Blood. 2009;113(12):2835–2842.  
54. Avecilla ST, Hattori K, Heissig B, et al. Chemokine-mediated interaction of 
hematopoietic progenitors with the bone marrow vascular niche is required for 
thrombopoiesis. Nat. Med. 2004;10(1):64–71.  
55. Pitchford SC, Lodie T, Rankin SM. VEGFR1 stimulates a CXCR4-dependent 
translocation of megakaryocytes to the vascular niche , enhancing platelet 
production in mice. 2012;120(14):2787–2795.  
56. Junt T, Schulze H, Chen Z, et al. Dynamic visualization of thrombopoiesis within 
bone marrow. Science (80-. ). 2007;317:1767–1770.  
57. Zhang L, Orban M, Lorenz M, et al. A novel role of sphingosine 1-phosphate 
receptor S1pr1 in mouse thrombopoiesis. J. Exp. Med. 2012;209(12):2165–2181.  
58. Italiano JE, Lecine P, Shivdasani R a., Hartwig JH. Blood platelets are assembled 
principally at the ends of proplatelet processes produced by differentiated 
megakaryocytes. J. Cell Biol. 1999;147(6):1299–1312.  
59. Choi ES, Nichol JL, Hokom MM, Hornkohl AC, Hunt P. Platelets generated in vitro 
from proplatelet-displaying human megakaryocytes are functional. Blood. 
1995;85(2):402–413.  
60. Behnke O. An Electron Microscope Study of the Rat Megacaryocyte. J. 
	  	  	   100 
Ultrastruct. Res. 1969;26:111–129.  
61. Becker RP, De Bruyn PPH. The transmural passage of blood cells into myeloid 
sinusoids and the entry of platelets into the sinusoidal circulation; a scanning 
electron microscopic investigation. Am. J. Anat. 1976;145(2):183–206.  
62. Thon JN, Montalvo A, Patel-Hett S, et al. Cytoskeletal mechanics of proplatelet 
maturation and platelet release. J. Cell Biol. 2010;191(4):861–874.  
63. Nishimura S, Nagasaki M, Kunishima S, et al. IL-1  induces thrombopoiesis 
through megakaryocyte rupture in response to acute platelet needs. J. Cell Biol. 
2015;209(3):453–466.  
64. Levine R, Eldor A, Schoff P, et al. Circulating megakaryocytes: Delivery of large 
numbers of intact, mature megakaryocytes to the lungs. Eur. J. Hematol. 
1993;51:233–246.  
65. Zucker-Franklin D, Philipp CS. Platelet production in the pulmonary capillary bed: 
new ultrastructural evidence for an old concept. Am. J. Pathol. 2000;157(1):69–
74.  
66. Kaufman RM, Airo R, Pollack S, Crosby WH. Circulating megakaryocytes and 
platelet release in the lung. Blood. 1965;26(6):720–731.  
67. Pedersen N. Occurrence of megakaryocytes in various vessels and their retention 
in the pulmonary capillaries in man. Scand. J. Haematol. 1978;21(5):369–375.  
68. Howell W, Donahue D. The production of blood platelets in the lungs. J. Expe. 
1937;65(2):177–203.  
69. Lefrançais E, Ortiz-Muñoz G, Caudrillier A, et al. The lung is a site of platelet 
biogenesis and a reservoir for haematopoietic progenitors. Nature. 2017;544:105–
109.  
70. Hall JG, Levin J, Kuhn JP, et al. Thrombocytopenia with absent radius (TAR). 
Medicine (Baltimore). 1969;48(6):411–439.  
71. de Alarcon PA, Graeve JA, Levine RF, McDonald TP, Beal DW. 
Thrombocytopenia and absent radii syndrome: defective megakaryocytopoiesis-
thrombocytopoiesis. Am. J. Pediatr. Hematol. Oncol. 1991;13(1):77–83.  
72. Letestu R, Vitrat N, Massé A, et al. Existence of a differentiation blockage at the 
stage of a megakaryocyte precursor in the thrombocytopenia and absent radii 
(TAR) syndrome. Blood. 2000;95(5):1633–1641.  
73. Homans A, Cohen J, Mazur E. Defective megakaryocytopoiesis in the syndrome 
of thrombocytopenia with absent radii. Br. J. Haematol. 1988;70:205–210.  
74. Hedberg VA, Lipton JM. Thrombocytopenia with absent radii. A review of 100 
cases. J. Pediatr. Hematol. Oncol. 1988;10(1):51–64.  
75. Albers C a, Paul DS, Schulze H, et al. Compound inheritance of a low-frequency 
regulatory SNP and a rare null mutation in exon-junction complex subunit RBM8A 
causes TAR syndrome. Nat. Genet. 2012;44(February):435–9, S1-2.  
76. Klopocki E, Schulze H, Strauss G, et al. Complex inheritance pattern resembling 
autosomal recessive inheritance involving a microdeletion in thrombocytopenia-
absent radius syndrome. Am. J. Hum. Genet. 2007;80(2):232–240.  
77. Le Hir H, Izaurralde E, Maquat LE, Moore MJ. The spliceosome deposits multiple 
proteins 20-24 nucleotides upstream of mRNA exon-exon junctions. EMBO J. 
2000;19(24):6860–6869.  
78. Kataoka N, Yong J, Kim VN, et al. Pre-mRNA splicing imprints mRNA in the 
nucleus with a novel RNA-binding protein that persists in the cytoplasm. Mol Cell. 
2000;6(3):673–682.  
79. Kim VN, Yong J, Kataoka N, et al. The Y14 protein communicates to the 
cytoplasm the position of exon-exon junctions. EMBO J. 2001;20(8):2062–2068.  
80. Le Hir H, Gatfield D, Izaurralde E, Moore MJ. The exon-exon junction complex 
	  	  	   101 
provides a binding platform for factors involved in mRNA export and nonsense-
mediated mRNA decay. EMBO J. 2001;20(17):4987–4997.  
81. Wiegand HL, Lu S, Cullen BR. Exon junction complexes mediate the enhancing 
effect of splicing on mRNA expression. Proc. Natl. Acad. Sci. U. S. A. 
2003;100(20):11327–11332.  
82. Palacios IM, Gatfield D, Johnston DS, Izaurralde E. An eIF4AIII-containing 
complex required for mRNA localization and       nonsense-mediated mRNA 
decay. Nature. 2004;427(February):753–757.  
83. Kim VN, Kataoka N, Dreyfuss G. Role of the nonsense-mediated decay factor 
hUpf3 in the splicing-dependent exon-exon junction complex. Science (80-. ). 
2001;293(5536):1832–1836.  
84. Lykke-Andersen J, Shu MD, Steitz JA. Communication of the position of exon-
exon junctions to the mRNA surveillance machinery by the protein RNPS1. 
Science (80-. ). 2001;293(5536):1836–1839.  
85. Salicioni AM, Xi M, Vanderveer LA, et al. Identification and structural analysis of 
human RBM8A and RBM8B: two highly conserved RNA-binding motif proteins 
that interact with OVCA1, a candidate tumor suppressor. Genomics. 
2000;69(1):54–62.  
86. Hachet O, Ephrussi A. Drosophila Y14 shuttles to the posterior of the oocyte and 
is required for oskar mRNA transport. Curr. Biol. 2001;11(21):1666–1674.  
87. Gaur M, Kamata T, Wang S, et al. Megakaryocytes derived from human 
embryonic stem cells: A genetically tractable system to study 
megakaryocytopoiesis and integrin function. J. Thromb. Haemost. 2006;4:436–
442.  
88. Takayama N, Nishikii H, Usui J, et al. Generation of functional platelets from 
human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that 
concentrate hematopoietic progenitors. Blood. 2008;111(11):5298–5306.  
89. Lu S, Li F, Yin H, et al. Platelets generated from human embryonic stem cells are 
functional in vitro and in the microcirculation of living mice. Cell Res. 
2011;21:530–545.  
90. Feng Q, Shabrani N, Thon JN, et al. Scalable generation of universal platelets 
from human induced pluripotent stem cells. Stem Cell Reports. 2014;3:817–831.  
91. Nakamura S, Takayama N, Hirata S, et al. Expandable megakaryocyte cell lines 
enable clinically applicable generation of platelets from human induced pluripotent 
stem cells. Cell Stem Cell. 2014;14:535–548.  
92. Matsunaga T, Tanaka I, Kobune M, et al. Ex vivo large-scale generation of human 
platelets from cord blood CD34+ cells. Stem Cells. 2006;24:2877–87.  
93. Pineault N, Robert A, Cortin V, Boyer L. Ex Vivo Differentiation of Cord Blood 
Stem Cells into Megakaryocytes and Platelets. Methods Mol. Biol. 2013;946:205–
224.  
94. Guerriero R, Testa U, Gabbianelli M, et al. Unilineage megakaryocytic 
proliferation and differentiation of purified hematopoietic progenitors in serum-free 
liquid culture. Blood. 1995;86(10):3725–3736.  
95. Johansson I, Stensballe J, Oliveri R, et al. How I treat patients with massive 
hemorrhage. Blood. 2014;124(20):3052–3059.  
96. Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion: A clinical 
practice guideline from the AABB. Ann. Intern. Med. 2015;162(3):205–213.  
97. Whitaker B, Rajbhandary S, Kleinman S, Harris A, Kamani N. Trends in United 
States blood collection and transfusion: results from the 2013 AABB Blood 
Collection, Utilization, and Patient Blood Management Survey. Transfusion. 
2016;56(9):2173–2183.  
	  	  	   102 
98. Stroncek DF, Rebulla P. Platelet transfusions. Lancet. 2007;370(9585):427–438.  
99. Tynngård N. Preparation, storage and quality control of platelet concentrates. 
Transfus. Apher. Sci. 2009;41(2):97–104.  
100. Stenberg P, Levin J. Mechanisms of platelet production. Blood Cells. 1989;15:23–
47.  
101. Robert A, Cortin V, Garnier A, Pineault N. Megakaryocyte and platelet production 
from human cord blood stem cells. Methods Mol. Biol. 2012;3:91–100.  
102. Thon JN, Mazutis L, Wu S, et al. Platelet bioreactor-on-a-chip. Blood. 
2014;124(12):1857–1867.  
103. Nakagawa Y, Nakamura S, Nakajima M, et al. Two differential flows in a 
bioreactor promoted platelet generation from human pluripotent stem cell-derived 
megakaryocytes. Exp. Hematol. 2013;41:742–748.  
104. Sullenbarger B, Bahng JH, Gruner R, Kotov N, Lasky LC. Prolonged continuous in 
vitro human platelet production using three-dimensional scaffolds. Exp. Hematol. 
2009;37(1):101–110.  
105. Avanzi MP, Oluwadara OE, Cushing MM, et al. A novel bioreactor and culture 
method drives high yields of platelets from stem cells. Transfusion. 
2016;56(1):170–178.  
106. Di Buduo CA, Wray LS, Tozzi L, et al. Programmable 3D silk bone marrow niche 
for platelet generation ex vivo and modeling of megakaryopoiesis pathologies. 
Blood. 2015;125(14):2254–2264.  
107. Strauss T, Sidlik-Muskatel R, Kenet G. Developmental hemostasis: Primary 
hemostasis and evaluation of platelet function in neonates. Semin. Fetal Neonatal 
Med. 2011;16(6):301–304.  
108. Israels SJ, Rand ML, Michelson AD. Neonatal Platelet Function. Semin Thromb 
Hemost. 2003;29(4):363–372.  
109. Rajasekhar D, Kestin AS, Bednarek FJ, et al. Neonatal platelets are less reactive 
than adult platelets to physiological agonists in whole blood. Thromb. Haemost. 
1994;72(6):957–963.  
110. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole 
blood using activation-dependent monoclonal antibodies and flow cytometry. 
Blood. 1987;70(1):307–315.  
111. Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet 
membrane glycoprotein IIb.IIIa complex during platelet activation. J. Biol. Chem. 
1985;260(20):11107–11114.  
112. Di Buduo C a., Wray LS, Tozzi L, et al. Programmable 3D silk bone marrow niche 
for platelet generation ex vivo and modeling of megakaryopoiesis pathologies. 
Blood. 2015;3:617–627.  
113. Wang Y, Hayes V, Jarocha D, et al. Comparative analysis of human ex vivo-
generated platelets vs megakaryocyte-generated platelets in mice: a cautionary 
tale. Blood. 2015;125(23):3627–3636.  
114. Chen J, Tan K, Zhou H, et al. Modifying murine von Willebrand factor A1 domain 
for in vivo assessment of human platelet therapies. Nat. Biotechnol. 
2007;26(1):114–119.  
115. Savage B, Saldívar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto 
fibrinogen or translocation on von Willebrand factor. Cell. 1996;84(2):289–297.  
116. Bertolini F, Battaglia M, Pedrazzoli P, et al. Megakaryocytic progenitors can be 
generated ex vivo and safely administered to autologous peripheral blood 
progenitor cell transplant recipients. Blood. 1997;89(8):2679–2688.  
117. Xi J, Zhu H, Liu D, et al. Infusion of Megakaryocytic Progenitor Products 
Generated from Cord Blood Hematopoietic Stem/Progenitor Cells: Results of the 
	  	  	   103 
Phase 1 Study. PLoS One. 2013;8(2):.  
118. Scheding S, Bergmannn M, Rathke G, et al. Additional transplantation of ex vivo 
generated megakaryocytic cells after high-dose chemotherapy. hematologica. 
2004;89:630–631.  
119. Mills JA, Paluru P, Weiss MJ, Gadue P, French DL. Hematopoietic differentiation 
of pluripotent stem cells in culture. Methods Mol. Biol. 2014;1185:181–194.  
120. Ivanciu L, Krishnaswamy S, Camire RM. New insights into the spatiotemporal 
localization of prothrombinase in vivo. Blood. 2014;124(11):1705–1714.  
121. Hockemeyer D, Soldner F, Beard C, et al. Efficient targeting of expressed and 
silent genes in human ESCs and iPSCs using zinc-finger nucleases. Nat. 
Biotechnol. 2009;27(9):851–7.  
122. Sim X, Cardenas-Diaz FL, French DL, Gadue P. A doxycyline-inducible system 
for genetic correction of iPSC disease models. Methods Mol. Biol. 2016;1353:13–
23.  
123. Mali P, Yang L, Esvelt KM, et al. RNA-Guided Human Genome Engineering via 
Cas9. Science (80-. ). 2013;339(6121):823–826.  
124. Veazey KJ, Golding MC. Selection of stable reference genes for quantitative RT-
PCR comparisons of mouse embryonic and extra-embryonic stem cells. PLoS 
One. 2011;6(11):.  
125. Reems J, Pineault N, Sun S. In vitro megakaryocyte production and platelet 
biogenesis: state of the art. Transfus. Med. Rev. 2010;24(1):33–43.  
126. Lee EJ, Godara P, Haylock D. Biomanufacture of human platelets for transfusion: 
Rationale and approaches. Exp. Hematol. 2014;42:332–346.  
127. Avanzi MP, Mitchell WB. Ex Vivo production of platelets from stem cells. Br. J. 
Haematol. 2014;165:237–247.  
128. Feng Q, Shabrani N, Thon JN, et al. Scalable Generation of Universal Platelets 
from Human Induced Pluripotent Stem Cells. Stem Cell Reports. 2014;3(5):817–
831.  
129. Lambert MP, Sullivan SK, Fuentes R, French DL, Poncz M. Challenges and 
promises for the development of donor-independent platelet transfusions. Blood. 
2013;121(17):3319–3324.  
130. Thon JN, Medvetz DA, Karlsson SM, Italiano JE. Road blocks in making platelets 
for transfusion. J. Thromb. Haemost. 2015;13(S1):S55–S62.  
131. Wang B, Zheng J. Platelet generation in vivo and in vitro. Springerplus. 
2016;5:787–797.  
132. Sim X, Poncz M, Gadue P, French DL. Understanding platelet generation from 
megakaryocytes: Implications for in vitro-derived platelets. Blood. 
2016;127(10):1227–1233.  
133. Tomer A, Harker L, Burstein S. Flow cytometric analysis of normal human 
megakaryocytes. Blood. 1988;71(5):1244–1252.  
134. Yamada E. The fine structure of the megakaryocyte in the mouse spleen. Acta 
Anat. 1957;29:267–290.  
135. Ru YX, Dong SX, Liang HY, Zhao SX. Platelet production of megakaryocyte: A 
review with original observations on human in vivo cells and bone marrow. 
Ultrastruct. Pathol. 2016;40(4):163–170.  
136. Takayama N, Nishimura S, Nakamura S, et al. Transient activation of c-MYC 
expression is critical for efficient platelet generation from human induced 
pluripotent stem cells. J. Exp. Med. 2010;207(13):2817–2830.  
137. Blin A, Le Goff A, Magniez A, et al. Microfluidic model of the platelet-generating 
organ: beyond bone marrow biomimetics. Sci. Rep. 2016;6:21700–21712.  
138. Fuentes R, Wang Y, Hirsch J, et al. Infusion of mature megakaryocytes into mice 
	  	  	   104 
yields functional platelets. J. Clin. Invest. 2010;120(11):3917–3922.  
139. Bergmeier W, Burger PC, Piffath CL, et al. Metalloproteinase inhibitors improve 
the recovery and hemostatic function of in vitro-aged or -injured mouse platelets. 
Blood. 2003;102(12):4229–4235.  
140. Bergmeier W, Piffath CL, Cheng G, et al. Tumor necrosis factor-α-converting 
enzyme (ADAM17) mediates GPIbα shedding from platelets in vitro and in vivo. 
Circ. Res. 2004;95:677–683.  
141. Fox JE. Shedding of adhesion receptors from the surface of activated platelets. 
Blood Coagul. Fibrinolysis. 1994;5:291–304.  
142. Michelson AD, Ellis PA, Barnard MR, et al. Downregulation of the platelet surface 
glycoprotein Ib-IX complex in whole blood stimulated by thrombin, adenosine 
diphosphate, or an in vivo wound. Blood. 1991;77(4):770–779.  
143. Bergmeier W, Rackebrandt K, Schroder W, Zirngibl H, Nieswandt B. Structural 
and functional characterization of the mouse von Willebrand factor receptor GPIb-
IX with novel monoclonal antibodies. Blood. 2000;95(3):886–893.  
144. Hartley PS, Savill J, Brown SB. The death of human platelets during incubation in 
citrated plasma involves shedding of CD42b and aggregation of dead platelets. 
Thromb. Haemost. 2005;95:100–106.  
145. Adachi M, Ryo R, Sato T, Yamaguchi N. Platelet factor 4 gene expression in a 
human megakaryocytic leukemia cell line (CMK) and its differentiated subclone 
(CMK11-5). Exp. Hematol. 1991;19:923–927.  
146. Eto K, Murphy R, Kerrigan SW, et al. Megakaryocytes derived from embryonic 
stem cells implicate CalDAG-GEFI in integrin signaling. Proc. Natl. Acad. Sci. U. 
S. A. 2002;99(20):12819–12824.  
147. Polgar J, Clemetson JM, Kehrel BE, et al. Platelet Activation and Signal 
Transduction by Convulxin, a C-type Lectin from Crotalus durissus terrificus 
(Tropical Rattlesnake) Venom via the p62/GPVI Collagen Receptor. Biochemistry. 
1997;272(21):13576–13583.  
148. Furman MI, Liu L, Benoit SE, et al. The cleaved peptide of the thrombin receptor 
is a strong platelet agonist. Proc. Natl. Acad. Sci. U. S. A. 1998;95(6):3082–3087.  
149. Wilson DB, Salem HH, Mruk JS, Maruyama I, Majerus PW. Biosynthesis of 
coagulation factor V by a human hepatocellular carcinoma cell line. J. Clin. Invest. 
1984;73:654–658.  
150. Mazzorana M, Baffet G, Kneip B, Launois B, Guguen-Guillouzo C. Expression of 
coagulation factor V gene by normal adult human hepatocytes in primary culture. 
Br. J. Haematol. 1991;78:229–235.  
151. Yang TL, Pipe SW, Yang A, Ginsburg D. Biosynthetic origin and functional 
significance of murine platelet factor V. Blood. 2003;102(8):2851–2855.  
152. Camire RM, Pollak ES, Kaushansky K, Tracy PB. Secretable human platelet-
derived factor V originates from the plasma pool. Blood. 1998;92(9):3035–3041.  
153. Gould WR, Simioni P, Silveira JR, et al. Megakaryocytes endocytose and 
subsequently modify human factor V in vivo to form the entire pool of a unique 
platelet-derived cofactor. J. Thromb. Haemost. 2005;3:450–456.  
154. Bouchard BA, Williams JL, Meisler NT, Long MW, Tracy PB. Endocytosis of 
plasma-derived factor V by megakaryocytes occurs via a clathrin-dependent, 
specific membrane binding event. J. Thromb. Haemost. 2005;3(3):541–551.  
155. Gertz JM, Bouchard B a. Mechanisms Regulating Acquisition of Platelet-Derived 
Factor V/Va by Megakaryocytes. J. Cell. Biochem. 2015;2126(March):2121–2126.  
156. Bouchard BA, Meisler NT, Nesheim ME, et al. A unique function for LRP-1: A 
component of a two-receptor system mediating specific endocytosis of plasma-
derived factor V by megakaryocytes. J. Thromb. Haemost. 2008;6:638–644.  
	  	  	   105 
157. Lambert MP, Wang Y, Bdeir KH, et al. Platelet factor 4 regulates 
megakaryopoiesis through low-density lipoprotein receptor-related protein 1 
(LRP1) on megakaryocytes. Blood. 2009;114(11):2290–2298.  
158. Thon JN, Macleod H, Begonja AJ, et al. Microtubule and cortical forces determine 
platelet size during vascular platelet production. Nat. Commun. 2012;3(May):852–
861.  
159. Michelson AD, Adelman B, Barnard MR, Carroll E, Handin RI. Platelet storage 
results in a redistribution of glycoprotein Ib molecules. J. Clin. Invest. 
1988;81:1734–1740.  
160. Hirata S, Murata T, Suzuki D, et al. Selective Inhibition of ADAM17 effectively 
mediates glycoprotein Iba retention during ex vivo generation of human induced 
pluripotent stem cell-derived platelets. Stem Cells Transl. Med. 2016;5:1–11.  
161. Caserta TM, Smith AN, Gultice AD, Reedy MA, Brown TL. Q-VD-OPh, a broad 
spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis. 
2003;8:345–352.  
162. Keoni CLI, Brown TL. Inhibition of apoptosis and efficacy of pan caspase inhibitor, 
Q-VD-OPh, in models of human disease. J. Cell Death. 2015;8:1–7.  
163. Sommer A, Kordowski F, Büch J, et al. Phosphatidylserine exposure is required 
for ADAM17 sheddase function. Nat. Commun. 2016;7(May):11523.  
164. Houwerzijl EJ, Blom NR, van der Want JJL, Vellenga E, de Wolf JTM. 
Megakaryocytic dysfunction in myelodysplastic syndromes and idiopathic 
thrombocytopenic purpura is in part due to different forms of cell death. Leukemia. 
2006;20:1937–1942.  
165. Sabri S, Foudi A, Boukour S, et al. Deficiency in the Wiskott-Aldrich protein 
induces premature proplatelet formation and platelet production in the bone 
marrow compartment. Blood. 2006;108(1):134–140.  
166. Morison IM, Cramer Bordé EM, Cheesman EJ, et al. A mutation of human 
cytochrome c enhances the intrinsic apoptotic pathway but causes only 
thrombocytopenia. Nat. Genet. 2008;40(4):387–389.  
167. Yang L, Wang L, Zhao CH, et al. Contributions of TRAIL-mediated megakaryocyte 
apoptosis to impaired megakaryocyte and platelet production in immune 
thrombocytopenia. Blood. 2010;116(20):4307–4316.  
168. Ru YX, Zhao SX, Liu EB, et al. Ultrastructural characteristics of bone marrow in 
patients with hematological disease: a study of 13 cases. Ultrastruct Pathol. 
2007;31(5):327–332.  
169. Schmitt A, Jouault H, Guichard J, et al. Pathologic interaction between 
megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood. 
2000;96(4):1342–1347.  
170. Reilly JT. Idiopathic myelofibrosis: Pathogenesis to treatment. Hematol. Oncol. 
2006;24(2):56–63.  
171. Kraytman M. Platelet size in thrombocytopenias and thrombocytosis of various 
origin. Blood. 1973;41(4):587–598.  
172. McDonald TP, Odell TT, Gosslee DG. Platelet size in relation to platelet age. 
Proc. Soc. Exp. Biol. Med. 1964;115:684–689.  
173. Louache F, Debili N, Cramer E, Breton-Gorius J, Vainchenker W. Fibrinogen is 
not synthesized by human megakaryocytes. Blood. 1991;77(2):311–316.  
174. Kile BT. The role of apoptosis in megakaryocytes and platelets. Br. J. Haematol. 
2014;165:217–226.  
175. De Botton S, Sabri S, Daugas E, et al. Platelet formation is the consequence of 
caspase activation within megakaryocytes. Blood. 2002;100(4):1310–1317.  
176. Clarke MCH, Savill J, Jones DB, Noble BS, Brown SB. Compartmentalized 
	  	  	   106 
megakaryocyte death generates functional platelets committed to caspase-
independent death. J. Cell Biol. 2003;160(4):577–587.  
177. White MJ, Schoenwaelder SM, Josefsson EC, et al. Caspase-9 mediates the 
apoptotic death of megakaryocytes and platelets, but is dispensable for their 
generation and function. Blood. 2012;119(18):4283–4290.  
178. Josefsson EC, Burnett DL, Lebois M, et al. Platelet production proceeds 
independently of the intrinsic and extrinsic apoptosis pathways. Nat. Commun. 
2014;5:3455–3469.  
179. Josefsson EC, James C, Henley KJ, et al. Megakaryocytes possess a functional 
intrinsic apoptosis pathway that must be restrained to survive and produce 
platelets. J. Exp. Med. 2011;208(10):2017–2031.  
180. Zappelli C, Van Der Zwaan C, Thijssen-Timmer DC, Mertens K, Meijer AB. Novel 
role for galectin-8 protein as mediator of coagulation factor V endocytosis by 
megakaryocytes. J. Biol. Chem. 2012;287(11):8327–8335.  
181. Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic 
lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of navitoclax 
in patients with relapsed or refractory disease. J. Clin. Oncol. 2012;30(5):488–
496.  
182. Wilson WH, Connor O a O, Czuczman MS, et al. Safety, Pharmacokinetics, 
Pharcodynamics, and Activity of Navitoclax, a Targeted High Affinity Inhibitor of 
BCL-2, in Lymphoid Malignancies. Lancet Oncol. 2010;11(12):1149–1159.  
183. Gandhi L, Camidge DR, De Oliveira MR, et al. Phase I study of navitoclax (ABT-
263), a novel bcl-2 family inhibitor, in patients with small-cell lung cancer and 
other solid tumors. J. Clin. Oncol. 2011;29(7):909–916.  
184. Chipuk JE, Bouchier-Hayes L, Green DR. Mitochondrial outer membrane 
permeabilization during apoptosis: the innocent bystander scenario. Cell Death 
Differ. 2006;13(8):1396–1402.  
185. Zamzami N, Marchetti P, Castedo M, et al. Inhibitors of permeability transition 
interfere with the disruption of the mitochondrial transmembrane potential during 
apoptosis. FEBS Lett. 1996;384(1):53–57.  
186. Yoshida T, Tomioka I, Nagahara T, et al. Bax-inhibiting peptide derived from 
mouse and rat Ku70. Biochem. Biophys. Res. Commun. 2004;321(4):961–966.  
187. Cassidy-Stone A, Chipuk JE, Ingerman E, et al. Chemical Inhibition of the 
Mitochondrial Division Dynamin Reveals Its Role in Bax/Bak-Dependent 
Mitochondrial Outer Membrane Permeabilization. Dev. Cell. 2008;14(2):193–204.  
188. Johnston I, Hayes V, Poncz M. Threading an elephant through the eye of a 
needle: Where are platelets made? Cell Res. 2017;1–2.  
189. Kennedy M, Awong G, Sturgeon CM, et al. T Lymphocyte Potential Marks the 
Emergence of Definitive Hematopoietic Progenitors in Human Pluripotent Stem 
Cell Differentiation Cultures. Cell Rep. 2012;2:1722–1735.  
190. Ditadi A, Sturgeon CM, Tober J, et al. Human definitive haemogenic endothelium 
and arterial vascular endothelium represent distinct lineages. Nat. Cell Biol. 
2015;17(5):580–591.  
191. Sturgeon CM, Ditadi A, Awong G, Kennedy M, Keller G. Wnt signaling controls 
the specification of definitive and primitive hematopoiesis from human pluripotent 
stem cells. Nat. Biotechnol. 2014;32(6):554–61.  
 
 
 
